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Abstract: Nucleoside analogues have found widespread application as antiviral and antitumor agents,
but not yet as antibacterials. Naturally occurring uridine-derived ‘nucleoside antibiotics’ target the
bacterial membrane protein MraY, an enzyme involved in peptidoglycan biosynthesis and a promising
target for the development of novel antibacterial agents. Muraymycins represent a nucleoside-peptide
subgroup of such MraY-inhibiting natural products. As part of detailed structure-activity relationship
(SAR) studies on muraymycins and their analogues, we now report novel insights into the effects
of stereochemical variations in the nucleoside core structure. Using a simplified version of the
muraymycin scaffold, it was shown that some formal inversions of stereochemistry led to about one
order of magnitude loss in inhibitory potency towards the target enzyme MraY. In contrast, epimers
of the core motif with retained inhibitory activity were also identified. These 5′,6′-anti-configured
analogues might serve as novel chemically tractable variations of the muraymycin scaffold for the
future development of uridine-derived drug candidates.
Keywords: antibiotics; natural products; nucleoside analogues; structure–activity relationships.
1. Introduction
Infections with bacterial strains that have developed resistance against clinically used antibiotics
are on the rise and represent a major challenge in healthcare [1,2]. New targets and new modes of action
are needed to fight back such infections. Such novel targets can also be found in bacterial pathways
that have already been addressed by many antibiotics [3]. MraY (translocase I) represents an example
of a yet unexploited target, as it is part of bacterial peptidoglycan biosynthesis, i.e., one of the main
pathways addressed by established antibiotics [4,5]. MraY catalyses the first membrane-associated
step of peptidoglycan formation: the reaction of UDP-MurNAc pentapeptide (‘Park’s nucleotide’) 1
with the isoprenoid membrane anchor undecaprenyl phosphate 2, thus yielding membrane-bound
lipid I 3 (Scheme 1) [6–12].
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Scheme 1. Reaction of Park’s nucleotide 1 with undecaprenyl phosphate 2 yielding lipid I 3 catalysed 
by translocase I (MraY). UDP = uridine diphosphate, UMP = uridine monophosphate. The exact 
composition of the pentapeptide moiety (residue R) can vary among different bacteria  [11]. 
MraY is a membrane protein with ten transmembrane helices and five cytosolic loops  [13,14]. 
Methods for overexpression and isolation of the protein are available [15–17]. Several classes of 
natural products that inhibit MraY have been found over the years (‘nucleoside antibiotics’, e.g., 
muraymycins, caprazamycins, liposidomycins, capuramycins , and mureidomycins) [12,18–20]. We 
are mainly interested in muraymycins and their synt hetic analogues, as they represent promising 
lead structures for antibacterial drug development. Muraymycins were originally discovered as a 
group of 19 structurally related secondary metabolites from Streptomyces [21,22]. Very recently, new 
and more active members of the muraymycins were isolated from the same strains [23]. The principle 
structure of muraymycins consists of a (5 ′S,6′S)-glycyluridine (GlyU) motif (representing a ′high-
carbon′  nucleoside) and a urea peptide moiety containing the arginine-derived non-proteinogenic 
amino acid epicapreomycidine, with both units connected by an alkyl linker (Figure 1). Many 
naturally occurring muraymycins carry an O-aminoribosyl residue at the nucleosidic 5′-position. 
Muraymycins have been assigned to four subclasses with respect to the central L-leucine motif: 
classes A–C feature a (3S)-3-hydroxyl-L-leucine that is further functionalised with fatty acyl motifs in 
the A- and B-series. The A-series has ω-functionalised fatty acyl units bearing a terminal (N-
hydroxy-)guanidine group (e.g., A1 4 and A5 5), whereas the B-series has branched alkyl chains 
instead (e.g., B9 6). The C-series (e.g., C4 7) is not O-acylated in the 3-hydroxyl-L-leucine moiety, and 
the D-series (e.g., D1 8) is characterised by a nonhydroxylated L-leucine residue. 
 
Figure 1. Structures of selected naturally occurring muraymycins 4–8 [21,23] and the previously 
reported synthetic 5′-deoxy analogue 9 [24]. 
In 2016, Chung et al. reported an X-ray crystal structure of MraY from the extremophile Aquifex 
aeolicus in complex with muraymycin D2 (which differs from D1 8 by the lack of the methyl ether at 
the amino ribose (Z), Figure 1) [25]. By comparison of this co-crystal structure with the previously 
described ligand-free apo enzyme structure [14], a pronounced conformational plasticity of the 
e . e ti it e l te l t l
t l . i i i te, i i sphate. t
i i e ti iety (resid e ) can vary a ong different bacteria [1 ].
MraY is a membrane protein with ten transmembrane helices and five cytosolic loops [13,14].
Methods for overexpression and isolation of the protein are available [15–17]. Several classes
of natural products that inhibit MraY have been found over the years (‘nucleoside antibiotics’,
e.g., muraymycins, caprazamycins, liposidomycins, capuramycins, and mureidomycins) [12,18–20].
We are mainly interested in muraymycins and their synthetic analogues, as they represent promising
lead structures for antibacterial drug development. Muraymycins were originally discovered as a group
of 19 structurally related secondary metabolites from Streptomyces [21,22]. Very recently, new and more
active members of the muraymycins were isolated from the same strains [23]. The principle structure
of muraymycins consists of a (5′S,6′S)-glycyluridine (GlyU) motif (representing a ′high-carbon′
nucleoside) and a urea peptide moiety containing the arginine-derived non-proteinogenic amino
acid epicapreomycidine, with both units connected by an alkyl linker (Figure 1). Many naturally
occurring muraymycins carry an O-aminoribosyl residue at the nucleosidic 5′-position. Muraymycins
have been assigned to four subclasses with respect to the central L-leucine motif: classes A–C feature a
(3S)-3-hydroxyl-L-leucine that is further functionalised with fatty acyl motifs in the A- and B-series.
The A-series hasω-functionalised fatty acyl units bearing a terminal (N-hydroxy-)guanidine group
(e.g., A1 4 and A5 5), whereas the B-series has branched alkyl chains instead (e.g., B9 6). The C-series
(e.g., C4 7) is not O-acylated in the 3-hydroxyl-L-leucine moiety, and the D-series (e.g., D1 8) is
characterised by a nonhydroxylated L-leucine residue.
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Figure 1. Structures of selected naturally occurring uray ycins 4–8 [21,23] and the previously
reported synthetic 5′-deoxy analogue 9 [24].
In 2016, Chung et al. reported an X-ray crystal structure of MraY from the extremophile Aquifex
aeolicus in complex with muraymycin D2 (which differs from D1 8 by the lack of the ethyl ether at
the amino ribose (Z), Figure 1) [25]. By comparison of this co-crystal structure with the previously
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described ligand-free apo enzyme structure [14], a pronounced conformational plasticity of the enzyme
was revealed, with some amino acids moving up to 17 Å upon inhibitor binding [25,26]. In combination
with the complex structures of the inhibitors, this makes computer-aided drug design approaches
challenging and less reliable for the prediction of binding modes and structure–activity relationship
(SAR) for other muraymycins and their analogues. Thus, the synthesis and biological testing of novel
analogues represents a crucial approach in obtaining additional and more detailed insights into the
interactions of muraymycin-type inhibitors with their bacterial target MraY.
The total synthesis of naturally occurring muraymycins is challenging with respect to several
unusual structural motifs in the muraymycin scaffold (in particular, the 5′-O-aminoribosylated
′high-carbon′ nucleoside core, the epicapreomycidine, and the (3S)-3-hydroxyl-L-leucine units).
Important contributions to the total synthesis of muraymycins and/or the aforementioned structural
motifs were made by Ichikawa and Matsuda, Kurosu, and our group [12,24,27–34]. Several
SAR studies on muraymycin analogues (including structurally simplified congeners) have already
been conducted [12,24,35–39]. For instance, Ichikawa, Matsuda, and coworkers showed that the
epicapreomycidine unit can be substituted with simpler amino acids without being deprived of
antibacterial activity. This finding was solely based on antibacterial minimum inhibitory concentrations
(MIC values), i.e., no in vitro data on MraY inhibition were reported for such analogues [38].
We have recently re-investigated selected naturally occurring muraymycins for their properties
as MraY inhibitors. By that, we showed that the lack of the fatty acid moiety (such as in 7 or 8)
eliminates antimicrobial activity (likely due to hampered cellular uptake) but hardly affects the target
interaction [40]. Regarding structural simplifications of the muraymycin scaffold, we have reported
5′-defunctionalised (‘5′-deoxy’) analogues of the uridine-derived muraymycin core unit, i.e., congeners
not only lacking the aminoribosyl motif, but any substituent in the 5′-position [24,41,42]. For the
5′-deoxy analogue 9 of muraymycin C4 7 (Figure 1), it was demonstrated that a corresponding
full-length muraymycin derivative of this type can still be a fairly potent inhibitor of MraY (IC50 =
95 ± 19 nM for 9) [40]. Thus, the 5′-deoxy variation might be useful to derive novel chemically more
tractable lead structures for antibacterial drug development. It might also serve as a simplified scaffold
for further SAR studies, for instance, on the muraymycin peptide unit.
However, it has been unknown so far if further variations of the nucleoside core structure might
be feasible without hampering inhibition of the target enzyme MraY. In particular, stereochemical
variations have only scarcely been studied. It was therefore the goal of this work to investigate
simplified muraymycin analogues with epimeric configurations in the ′high-carbon′ uridine-derived
nucleoside core. During our studies on 5′-deoxy analogue 9, we have made the unexpected observation
that 5′-hydroxylated synthetic intermediates (i.e., protected uridine-derived building blocks with the
native (5′S,6′S)-syn-configuration) were fairly unstable and therefore prone to decomposition [24].
Based on the assumption that the intrinsic instability of these intermediates originates from their
5′,6′-syn-configuration, we turned to the respective 5′,6′-anti-configured congeners. Thus, another
objective was to investigate if epimeric anti-configured variations ((5′R,6′S) and (5′S,6′R), respectively)
might be sufficiently stable for the synthesis of full-length muraymycins and if the resultant analogues
would be MraY inhibitors. Finally, we also aimed to study the interplay of stereochemical variations in
the nucleoside core and an epimeric configuration in the peptide unit. We therefore decided to include
D-leucine derivatives (in contrast to the native L-configuration in this position) in our studies.
The aforementioned considerations led to the design of target structures 10–17 (Scheme 2). In order
to limit synthetic effort, the scaffold of the previously reported 5′-deoxy analogue 9 was further
simplified (L-lysine instead of the cyclic arginine derivative epicapreomycidine, nonhydroxylated
L-leucine (as in muraymycin D1 8) in the central section), thus furnishing analogue 10 with the native
(6′S)-configuration in the nucleoside core. Compound 11 represents the leucine (i.e., 2′ ′ ′) epimer
of 10, and target structures 12 and 13 are the 6′-epimers of 10 and 11, respectively. Compounds
14-17 are anti-configured 5′-hydroxylated analogues with one epimeric configuration (relative to
the 5′,6′-syn-configured natural products) in either the 5′- or the 6′-position. In the case of 15 and
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17, this variation was combined with the non-natural D-leucine (i.e., (2′ ′ ′R)) motif. It was our goal
to prepare this series of muraymycin analogues in an efficient manner and to subject them to an
established fluorescence-based in vitro assay for MraY inhibition [15,40,43]. Thus, we wanted to
identify stereochemical variations of the muraymycin scaffold with potentially retained inhibitory
activities towards the bacterial target enzyme MraY.
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2. Results
2.1. Synthesis of Muraymycin Epimers
For our previous synthesis of 5′-deoxy muraymycin analogue 9, we had reported a tripartite
approach using protected building blocks for the uridine-derived nucleoside core, the terminal urea
dipeptide motif and the central section [24]. However, for the sake of efficiency, we have decided to
pursue a bipartite strategy in this work as most of the structural variations would be in the nucleoside
core. Hence, such a bipartite approach was envisioned to be more convergent. The dissection of
target structures 10–17 into two principle building blocks led to the protected urea tripeptide 18 and
aminoalkylated nucleosyl amino acids 19–22 (Scheme 2). Peptide coupling and subsequent global
acidic deprotection of the two building blocks was envisaged to afford the target compounds. It was
initially unclear if the peptide coupling of 18 with either uridine derivative 19–22 proceeds without
epimerisation. Hence, it was decided to prepare the L-leucine-containing tripeptide 18 first in order
to initially elucidate the stereochemical outcome of the key coupling reaction before preparing the
D-leucine-containing derivative of 18.
Protected urea tripeptide 18 was synthesised from corresponding amino acid
building blocks (Scheme 3). Commercially available Nα-Cbz-Nε-Boc-protected L-lysine
23 was converted into its 2-(trimethylsilyl)ethyl (TMSE) ester using a sequence of
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC)-mediated esterification
and Nα-Cbz deprotection (77% yield over two steps). The resultant product 24 was coupled with
N-(S-methyl thiocarbonyl)-L-valine-tert-butyl ester 25 [28] in the presence of silver triflate to give 26
in 76% yield. TMSE deprotection with tetrabutylammonium fluoride (TBAF) then afforded the free
carboxylic acid 27 in 93% yield. Urea dipeptide 27 was coupled with L-leucine TMSE ester 28 (TFA
salt) to give urea tripeptide ester 29 in 80% yield. Subsequent cleavage of the TMSE ester furnished the
urea tripeptide building block 18 in 92% yield. The L-leucine TMSE ester 28 had been obtained in a
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similar manner as its L-lysine congener from N-Cbz-L-leucine 30 via a sequence of EDC-mediated
esterification and N-Cbz deprotection (86% yield over 2 steps, Scheme 3).Molecules 2018, 23, x FOR PEER REVIEW  5 of 19 
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The stereocontrolled synthesis of the a inoalkylated 5′-deoxy nucleosyl amino acids 19 and 20
has been reported before [41]. For the preparatio f t e ′- r xylated building blocks 21 and 22,
we have employed our previously described te e ll ses of corresponding epoxy ester
precursors [44]. In the case of 6′-epimer 21, epo t i d via stereoselective reaction
of a sulphur ylide with a uridine-5′-aldehyde re ot shown) [31,45–47]. Epoxide 31
was then reacted with N1-(Cbz)-1,3-diaminopropa i i lective SN2-type transformation
affording amino alcohol 33 in 77% yield (Sche e 4). se uent N-Cbz deprotection (99% yield) gave
the 6′-epi building block 21. For 5′-epimer 22, epoxy ester 34 as obtained via Sharpless epoxidation
(reactions not shown) [44,47]. Epoxide 34 was then subjected to a similar sequence of regioselective
SN2-type ring opening (product 35, 89% yield) and N-Cbz deprotection (99% yield) to afford the 5′-epi
building block 22 (Scheme 4).
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With all required building blocks in hand, the target structures could be prepared. The urea
tripeptide building block 18 was activated with EDC in the presence of HOBt and then treated with
amines 19–22 (Scheme 5). Corresponding coupling products were not characterised but directly
employed in global acidic deprotections with 80% TFA in water. For each two-step transformation
of this type, two compounds were isolated by preparative HPLC, showing identical masses and
connectivities (as proven by NMR spectroscopy). It was concluded that the activated leucine unit
in tripeptide 18 must have undergone epimerisation in the coupling step, which implied that the
respective L-leucine and D-leucine epimers were isolated in pure form (after HPLC) from just one
two-step transformation for every variation of the nucleoside core. This was unambiguously proven by
acidic hydrolysis of the respective stereoisomerically pure peptidic products, subsequent derivatisation
with Marfey’s reagent and HPLC analysis, which also furnished the stereochemical assignment of
the leucine unit (see Supplementary Materials). Hence, it was not necessary to prepare the D-leucine
epimer of 18 as all target structures (10–17) were synthesised from one urea tripeptide precursor in a
highly efficient manner (Scheme 5).
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2.2. Biological Evaluation
Target compounds 10–17 were tested in vitro for their inhibitory potency towards the bacterial
target enzyme MraY. Therefore, a previously reported fluorescence-based assay was employed,
using dansylated Park’s nucleotide and MraY from S. aureus (recombinantly overexpressed in
E. coli) [15,23,40,43,48]. None of the tested muraymycin analogues showed any interfering
autofluorescence at the employed wavelength (λex = 355 nm). The thus obtained inhibitory activities
(IC50 values) are listed in Table 1.
Muraymycin analogues 10–17 were also studied for their antibacterial activities against E. coli,
but were not active (MIC > 50 µg/mL). This was in agreement with the results obtained for previously
reported 5′-deoxy analogue 9 (which proved to be more potent as an MraY inhibitor) which was
weakly active against bacterial growth [24].
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Table 1. In vitro inhibitory activities of muraymycin analogues 10–17 against MraY from S. aureus.
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that exchanging the epicapreomycidine moiety to simpler amino acids preserves inhibitor potency to 
a large extent, even though this finding was mainly based on antibacterial activities (MIC values) [38]. 
In our series of 5′-deoxy analogues, replacing epicapreomycidine for L-lysine and inserting 
nonhydroxylated L-leucine in the central position led to a 26-fold loss in inhibitory potency 
(compounds 10 vs. 9). However, this implied that 10 was still a reasonably potent (i.e., low μM) MraY 
inhibitor. 
A comparison of MraY inhibitory activities of 10–17 (Table 1) revealed that the configuration of 
the leucine moiety had only a weak influence on inhibitory potencies, with the notable exception of 
16 vs. 17. In this case, the native L-configuration was preferred as 16 was 3-fold more active than 17. 
The reason for this is not fully clear, but it is possible that the non-native (5′R)-configuration in 16 and 
17 might lead to a slightly different binding mode of these MraY inhibitors relative to 10–13 (5′-deoxy) 
as well as 14 and 15 (5′S). The influence of the configuration in the 6 ′-position was much more 
pronounced with the most distinct difference for the 5 ′-deoxy (6′R)-derivatives 12 and 13 (which were 
15-fold and 12-fold weaker inhibitors than their (6 ′S)-counterparts 10 and 11, respectively). This 
decrease in inhibitory potency of the (6′R)-configured analogues was largely compensated by the 
presence of a 5′-hydroxy group if the latter was oriented in the native (5 ′S)-configuration (analogues 
14 and 15). Interestingly, the (5′R,6′S)-analogue 16 also showed almost completely retained activity, 
suggesting that at least one of the two substituents at the 5 ′- and 6′-position needs to be in its natural 
orientation (in the 5′-hydroxylated series of compounds). 
In conclusion, these results indicate that the effect of formal stereochemical inversions in the 
muraymycin nucleoside core (relative to the native scaffold) on MraY inhibition can be limited if a 
suitable structural motif is chosen. This is particularly t he case for 5′ ,6′-anti-configured 5′-hydroxy 
analogues (except for D-leucine congener 17). This series of compounds turned out to be stable and 
chemically tractable, in contrast to the previously reported native (5 ′S,6′S)-syn-configured motif and 
Compound R
Configuration
IC50 [µM] 15′ 6′ 2′′′ (Leu)
10 H - S S 2.5 ± 0.6
11 H - S R 2.0 ± 0.6
12 H - R S 38 ± 6
13 H - R R 24 ± 9
14 OH S R S 10 ± 4
15 OH S R R 10 ± 2
16 OH R S S 6.2 ± 2.8
17 OH R S R 21 ± 4
deoxy-C4 9 2 H - S S 0.095 ± 0.019
1 A crude membrane preparation of MraY from S. aureus, heterologously overexpressed in E. coli, was used.
All measurements were carried out in triplicates. Shown data represent mean values ± standard deviations.
2 Structure shown in Figure 1.
3. Discussion
All newly synthesised muraymycin epimers 10–17 showed µM inhibitory activities in vitro against
the bacterial target protein MraY. This is in accordance with previously reported observations that
exchanging the epicapreomycidine moiety to simpler amino acids preserves inhibitor potency to a large
extent, even though this finding was mainly based on antibacterial activities (MIC values) [38]. In our
series of 5′-deoxy analogues, replacing epicapreomycidine for L-lysine and inserting nonhydroxylated
L-leucine in the central position led to a ~26-fold loss in inhibitory potency (compounds 10 vs. 9).
However, this implied that 10 was still a reasonably potent (i.e., low µM) MraY inhibitor.
A comparison of MraY inhibitory activities of 10–17 (Table 1) revealed that the configuration of
the leucine moiety had only a weak influence on inhibitory potencies, with the notable exception of
16 vs. 17. In this case, the native L-configuration was preferred as 16 was ~3-fold more active than
17. The reason for this is not fully clear, but it is possible that the non-native (5′R)-configuration in
16 and 17 might lead to a slightly different binding mode of these MraY inhibitors relative to 10–13
(5′-deoxy) as well as 14 and 15 (5′S). The influence of the configuration in the 6′-position was much
more pronounced with the most distinct difference for the 5′-deoxy (6′R)-derivatives 12 and 13 (which
were 15-fold and 12-fold weaker inhibitors than their (6′S)-counterparts 10 and 11, respectively). This
decrease in inhibitory potency of the (6′R)-configured analogues was largely compensated by the
presence of a 5′-hydroxy group if the latter was oriented in the native (5′S)-configuration (analogues
14 and 15). Interestingly, the (5′R,6′S)-analogue 16 also showed almost completely retained activity,
suggesting that at least one of the two substituents at the 5′- and 6′-position needs to be in its natural
orientation (in the 5′-hydroxylated series of compounds).
In conclusion, these results indicate that the effect of formal stereochemical inversions in the
muraymycin nucleoside core (relative to the native scaffold) on MraY inhibition can be limited if a
suitable structural motif is chosen. This is particularly the case for 5′,6′-anti-configured 5′-hydroxy
analogues (except for D-leucine congener 17). This series of compounds turned out to be stable and
chemically tractable, in contrast to the previously reported native (5′S,6′S)-syn-configured motif and its
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intrinsic lability [24]. The synthesis of (5′S,6′R)-derivatives 14 and 15 was particularly straightforward
and efficient, as their epoxy ester precursor 31 is readily accessible [44].
The primary goal of the reported study was to further elucidate MraY inhibition and not to
obtain analogues with strong antibacterial potencies. It was anticipated that the target structures 10–17
would only show very weak antibacterial activities at best, as previously reported derivative 9 (which
was a stronger MraY inhibitor) had already only been moderately active in inhibiting bacterial cell
growth [24]. Indeed, 10–17 were devoid of activity against E. coli (MIC > 50 µg/mL). The comparison
with 9 as well as with naturally occurring muraymycins [40] indicates that a low-nM (or stronger)
inhibitory potency of this compound class against MraY appears to be a prerequisite for reasonable
antibacterial activity. It needs to be taken into account that the polar muraymycin scaffold surely
hampers cellular uptake, thus making it a decisive bottleneck for antibacterial potency. However,
the novel variations of the muraymycin structure identified in this work will be highly useful for future
SAR studies and the development of muraymycin analogues with improved MraY inhibition. In a
second step, one can then aim to improve bacterial cellular uptake, for instance, by lipophilisation of
the polar muraymycin scaffold. Such a strategy is envisioned to finally provide antibacterially active
muraymycin analogues with improved chemical tractability as antimicrobial drug candidates.
4. Materials and Methods
4.1. Synthesis of Muraymycin Epimers
General methods: All chemicals were purchased from standard suppliers. Reactions involving
oxygen and/or moisture sensitive reagents were carried out under an atmosphere of argon using
anhydrous solvents. Anhydrous solvents were obtained in the following manner. THF was dried over
sodium/benzophenone and distilled, CH2Cl2 was dried over CaH2 and distilled, MeOH was dried
over activated molecular sieves (3 Å) and degassed. The obtained solvents were stored over molecular
sieves (4 Å; in case of MeOH 3 Å). All other solvents were of technical quality and distilled prior to
use, and deionised water was used throughout. Column chromatography was carried out on silica
gel 60 (0.040–0.063 mm, 230–400 mesh ASTM, VWR, Darmstadt, Germany) under flash conditions
except where indicated. TLC was performed on aluminium plates precoated with silica gel 60 F254
(VWR, Darmstadt, Germany). Visualisation of the spots was carried out using UV light (254 nm)
and/or staining under heating (H2SO4 staining solution: 4 g vanillin, 25 mL conc. H2SO4, 80 mL
AcOH, and 680 mL MeOH; KMnO4 staining solution: 1 g KMnO4, 6 g K2CO3, and 1.5 mL 1.25 M
NaOH solution, all dissolved in 100 mL H2O; ninhydrin staining solution: 0.3 g ninhydrin, 3 mL
AcOH, and 100 mL 1-butanol). Analytical HPLC was performed on a VWR-Hitachi system equipped
with an L-2300 pump, an L-2200 autosampler, an L-2300 column oven (24 ◦C), an L-2455 Diode Array
Detector (DAD), and a LiChroCartTM column (4 × 125 mm) containing reversed phase silica gel
PurospherTM RP18e (5 µm) purchased from VWR (Darmstadt, Germany). The exact HPLC method is
given in the Supplementary Materials. Preparative HPLC was carried out on a Jasco system equipped
with a DG-2080-53 degasser, two PU-2080 Plus pumps, a UV-2075 Plus UV/Vis detector (detection at
260 nm), and a column (21 × 250 mm) containing reversed phase silica gel Nucleodur™ 100-5 C18ec
(5 µm) purchased from Macherey-Nagel (Düren, Germany). Method: eluent A water (+0.1% TFA),
eluent B 80:20 MeCN:water (+0.1% TFA); 0–30 min gradient of B (10–60%), 30–32 min gradient of B
(60–100%), 32–40 min 100% B, 40–42 min gradient of B (100–5%), 42–51 min 5% B; flow 10 mL/min.
300 MHz- and 600 MHz-1H, and 75 MHz- and 126 MHz-13C, as well as 282 MHz-19F NMR spectra
were recorded on Varian MERCURY 300, UNITY 300, and INOVA 600 spectrometers (Varian, Palo
Alto, CA, USA). All 13C and 19F NMR spectra were 1H-decoupled. All spectra were recorded at room
temperature except of samples in DMSO-d6 and D2O (standard 35 ◦C) and where indicated otherwise
and were referenced internally to solvent reference frequencies wherever possible. Chemical shifts (δ)
are quoted in ppm and coupling constants (J) are reported in Hz. Assignment of signals was carried
out using H,H-COSY, HSQC, and HMBC spectra obtained on the spectrometers mentioned above.
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The numbering of atoms of muraymycin target structure is depicted in the Supplementary Material
(Figure S20). Mass spectra of small molecules were measured on a Finnigan LCQ ion-trap mass
spectrometer or on a Bruker microTOF spectrometer (Bremen, Germany). For ESI measurements in
the negative mode, solutions of the compounds in pure MeOH were used, whereas for measurements
in the positive mode, solutions in MeOH containing 0.1% formic acid were used. High resolution
spectra were measured on a Bruker 7 Tesla Fourier transform ion cyclotron resonance (FTICR) mass
spectrometer (Bruker, Bremen, Germany). Melting points (mp) were measured on a Büchi instrument
(Büchi, Essen, Germany) and are not corrected. Optical rotations were recorded on a PerkinElmer
polarimeter 241 (Perkin-Elmer, Hamburg, Germany) with a Na source using a 10 cm cell. Solutions of
the compounds (~10 mg) in CHCl3, MeOH, or water (1 mL) were used, and concentrations are given
in g/100 mL. Infrared spectroscopy (IR) was performed on a Jasco (Pfungstadt, Germany) FT/IR-4100
spectrometer equipped with an integrated ATR unit (GladiATR™, PIKE Technologies, Madison WI,
USA). Wavenumbers (ν) are quoted in cm−1. UV spectroscopy of small molecules was carried out on
a PerkinElmer (Hamburg, Germany) Lambda 2 spectrometer. Measurements were performed with
solutions of ~0.1 mg of the compound in 10 mL MeCN, MeOH, or water and in the range of 190
to 500 nm. Wavelengths of maximum absorption (λmax) are reported in nm with the corresponding
logarithmic molar extinction coefficient (log ε, ε/dm3 mol−1 cm−1) given in parenthesis.
5′-deoxy-L-Leu muraymycin analogue (10) and 5′-deoxy-D-Leu muraymycin analogue (11): To a
solution of the urea tripeptide 18 (10 mg, 0.018 mmol) in THF (2.5 mL), 1-hydroxybenzotriazole
(HOBt, 2.4 mg, 0.018 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (ECD,
3.5 mg, 0.018 mmol), and N,N-diisopropylethylamine (DIPEA, 3.1 µL, 0.018 mmol) were added and
the mixture was stirred at room temperature for 30 min. It was then added to a solution of amine 19
(15 mg, 0.023 mmol) in THF (2 mL) and stirred at room temperature for 20 h. EtOAc (30 mL) was
added and the solution was washed with sat. NaHCO3 (30 mL). The organic layer was dried over
Na2SO4 and the solvent was removed under reduced pressure. The protected analogues of 10 and
11 were obtained after column chromatography (98:2–95:5, CH2Cl2-MeOH) as colourless solids. This
material was dissolved in TFA (80% in water, 2.7 mL) and stirred at room temperature for 24 h. Water
(10 mL) was added and the solvent was removed under reduced pressure. The muraymycin analogues
10 (10 mg, 57%) and 11 (3.1 mg, 17%) were separated by preparative HPLC (10: tR = 17.9 min, 11: tR =
16.5 min) and obtained as colourless solids. 10: 1H NMR (600 MHz, D2O, 35 ◦C): δ [ppm] = 0.99 (d, J =
6.0 Hz, 3H, 5′ ′ ′-Ha), 1.04 (d, J = 6.0 Hz, 3H, 5′ ′ ′-Hb), 1.05 (d, J = 7.1 Hz, 3H, 4′ ′ ′ ′ ′-Ha), 1.08 (d, J = 6.6 Hz,
3H, 4′ ′ ′ ′ ′-Hb), 1.51–1.60 (m, 2H, 4′ ′ ′ ′-H), 1.66–1.83 (m, 6H, 3′ ′ ′-H, 4′ ′ ′-H, 3′ ′ ′ ′-Ha, 5′ ′ ′ ′-H), 1.88–1.94 (m,
1H, 3′ ′ ′ ′-Hb), 2.04 (dddd, J = 7.4, 7.2, 6.6, 6.4 Hz, 2H, 2′ ′-H), 2.28 (dqq, J = 7.1, 6.6, 6.2 Hz, 1H, 3′ ′ ′ ′ ′-H),
2.43 (ddd, J = 15.0, 9.7, 6.2 Hz, 1H, 5′-Ha), 2.59 (ddd, J = 15.0, 6.7, 2.3 Hz, 1H, 5′-Hb), 3.12 (dd, J = 7.6,
7.6 Hz, 2H, 6′ ′ ′ ′-H), 3.22 (dd, J = 7.4, 7.2 Hz, 2H, 1′ ′-H), 3.37 (ddd, J = 14.1, 6.6, 6.4 Hz, 1H, 3′ ′-Ha),
3.44 (ddd, J = 14.1, 6.6, 6.4 Hz, 1H, 3′ ′-Hb), 4.10 (dd, J = 6.7, 6.2 Hz, 1H, 6′-H), 4.20–4.23 (m, 2H, 3′-H,
2′ ′ ′ ′ ′-H), 4.24 (dd, J = 8.7, 5.4 Hz, 1H, 2′ ′ ′ ′-H), 4.29 (ddd, J = 9.7, 6.0, 2.3 Hz, 1H, 4′-H), 4.38 (dd, J = 10.8,
4.6 Hz, 1H, 2′ ′ ′-H), 4.56 (dd, J = 5.8, 4.0 Hz, 1H, 2′-H), 5.87 (d, J = 4.0 Hz, 1H, 1′-H), 6.01 (d, J = 8.1 Hz,
1H, 5-H), 7.76 (d, J = 8.1 Hz, 1H, 6-H). 13C NMR (126 MHz, D2O, 35 ◦C): δ [ppm] = 19.69 (Ca-4′ ′ ′ ′ ′),
21.18 (Cb-4′ ′ ′ ′ ′), 23.37 (Ca-5′ ′ ′), 24.71 (C-4′ ′ ′ ′), 24.79 (Cb-5′ ′ ′), 27.09 (C-4′ ′ ′), 28.30 (C-2′ ′), 28.93 (C-5′ ′ ′ ′),
32.64 (C-3′ ′ ′ ′ ′), 33.41 (C-3′ ′ ′ ′), 35.29 (C-5′), 38.64 (C-3′ ′), 41.92 (C-6′ ′ ′ ′), 42.23 (C-3′ ′ ′), 46.93 (C-1′ ′), 55.20
(C-2′ ′ ′), 56.75 (C-2′ ′ ′ ′), 61.50 (C-2′ ′ ′ ′ ′), 61.73 (C-6′), 75.18 (C-2′), 75.55 (C-3′), 82.46 (C-4′), 94.41 (C-1′),
104.84 (C-5), 118.93 (q, 1JCF = 292.3 Hz, TFA-CF3), 145.32 (C-6), 153.89 (C-2), 161.95 (NC(=O)N), 165.36
(q, 2JCF = 35.3 Hz, TFA-COO), 168.58 (C-4), 173.96 (C-7′), 177.32 (C-1′ ′ ′), 177.79 (C-1′ ′ ′ ′), 179.05 (C-1′ ′ ′ ′ ′).
19F NMR (282 MHz, D2O, 35 ◦C): δ [ppm] = −72.86 (TFA-CF3). MS (ESI-): m/z = 741.4 [M − H]−.
HRMS (ESI)−: calcd.: 741.3788 [M − H]−, found: 741.3792. IR (ATR): ν = 1638, 1551, 1198, 1182, 1131,
799, 720, 551, 519. UV (H2O): λmax (log ε) = 260 (4.01). Optical rotation: [α]D25 = −1.1 (c = 0.46, H2O).
m.p. = 208 ◦C. 11: 1H NMR (600 MHz, D2O, 35 ◦C): δ [ppm] = 0.98 (d, J = 6.1 Hz, 3H, 5′ ′ ′-Ha), 1.04 (d, J
= 5.9 Hz, 3H, 5′ ′ ′-Hb), 1.04 (d, J = 6.9 Hz, 3H, 4′ ′ ′ ′ ′-Ha), 1.08 (d, J = 6.7 Hz, 3H, 4′ ′ ′ ′ ′-Hb), 1.50–1.63 (m,
2H, 4′ ′ ′ ′-H), 1.66–1.85 (m, 6H, 3′ ′ ′-H, 4′ ′ ′-H, 3′ ′ ′ ′-Ha, 5′ ′ ′ ′-H), 1.87–1.93 (m, 1H, 3′ ′ ′ ′-Hb), 1.97–2.07 (m,
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2H, 2′ ′-H), 2.27 (dqq, J = 6.9, 6.7, 5.7 Hz, 1H, 3′ ′ ′ ′ ′-H), 2.36 (ddd, J = 15.1, 10.0 Hz, 6.6 Hz, 1H, 5′-Ha),
2.54 (ddd, J = 15.1, 6.5 Hz, 3.0 Hz, 1H, 5′-Hb), 3.11 (dd, J = 7.6, 7.6 Hz, 2H, 6′ ′ ′ ′-H), 3.16 (ddd, J = 13.2,
8.8, 7.9 Hz, 1H, 1′ ′-Ha), 3.21 (ddd, J = 13.2, 8.0, 6.5 Hz, 1H, 1′ ′-Hb), 3.38 (ddd, J = 14.2, 6.5, 6.4 Hz, 1H,
3′ ′-Ha), 3.41 (ddd, J = 14.2, 7.0, 6.5 Hz, 1H, 3′ ′-Hb), 3.93 (dd, J = 6.6, 6.5 Hz, 1H, 6′-H), 4.17 (d, J = 5.7 Hz,
1H, 2′ ′ ′ ′ ′-H), 4.20 (dd, J = 6.4, 5.9 Hz, 1H, 3′-H), 4.24 (dd, J = 8.2, 6.0 Hz, 1H, 2′ ′ ′ ′-H), 4.28 (ddd, J = 10.0,
6.4, 3.0 Hz, 1H, 4′-H), 4.35 (dd, J = 10.4, 4.1 Hz, 1H, 2′ ′ ′-H), 4.54 (dd, J = 5.9, 3.8 Hz, 1H, 2′-H), 5.88 (d,
J = 3.8 Hz, 1H, 1′-H), 6.01 (d, J = 8.1 Hz, 1H, 5-H), 7.77 (d, J = 8.1 Hz, 1H, 6-H). 13C NMR (126 MHz,
D2O, 35 ◦C): δ [ppm] = 19.74 (Ca-4′ ′ ′ ′ ′), 21.23 (Cb-4′ ′ ′ ′ ′), 22.99 (Ca-5′ ′ ′), 24.78 (C-4′ ′ ′ ′), 24.94 (Cb-5′ ′ ′),
27.13 (C-4′ ′ ′), 28.33 (C-2′ ′), 28.93 (C-5′ ′ ′ ′), 32.65 (C-3′ ′ ′ ′ ′), 33.50 (C-3′ ′ ′ ′), 35.77 (C-5′), 38.53 (C-3′ ′), 41.90
(C-6′ ′ ′ ′), 42.18 (C-3′ ′ ′), 46.87 (C-1′ ′), 55.21 (C-2′ ′ ′), 56.84 (C-2′ ′ ′ ′), 61.77 (C-2′ ′ ′ ′ ′), 62.91 (C-6′), 75.22 (C-2′),
75.51 (C-3′), 82.94 (C-4′), 94.32 (C-1′), 104.87 (C-5), 118.93 (q, 1JCF = 292.3 Hz, TFA-CF3), 145.32 (C-6),
153.91 (C-2), 161.82 (NC(=O)N), 165.41 (q, 2JCF = 34.0 Hz, TFA-COO), 168.59 (C-4), 174.75 (C-7′), 177.53
(C-1′ ′ ′), 178.10 (C-1′ ′ ′ ′), 179.42 (C-1′ ′ ′ ′ ′). 19F NMR (282 MHz, D2O, 35 ◦C): δ [ppm] = −72.87 (TFA-CF3).
MS (ESI+): m/z = 743.5 [M + H]+. HRMS (ESI+): calcd.: 743.3934 [M + H]+, found: 743.3926. IR (ATR):
ν [cm−1] = 1641, 1552, 1200, 1182, 1131, 799, 720, 550, 517. UV (H2O): λmax (log ε) = 261 (4.07). Optical
rotation: [α]D25 = +31.4 (c = 0.14, H2O). m.p. = 211 ◦C.
5′-deoxy-6′-epi-L-Leu muraymycin analogue (12) and 5′-deoxy-6′-epi-D-Leu muraymycin analogue
(13): To a solution of the urea tripeptide 18 (10 mg, 0.018 mmol) in THF (2.5 mL), HOBt (2.4 mg,
0.018 mmol), ECD (3.5 mg, 0.018 mmol), and DIPEA (3.1 µL, 0.018 mmol) were added and the mixture
was stirred at room temperature for 30 min. It was then added to a solution of amine 20 (15 mg,
0.023 mmol) in THF (2 mL) and stirred at room temperature for 20 h. EtOAc (30 mL) was added
and the solution was washed with sat. NaHCO3 (30 mL). The organic layer was dried over Na2SO4
and the solvent was removed under reduced pressure. The protected analogues of 12 and 13 were
obtained after column chromatography (98:2–95:5, CH2Cl2-MeOH) as colourless solids. This material
was dissolved in TFA (80% in water, 2.7 mL) and stirred at room temperature for 24 h. Water (10 mL)
was added and the solvent was removed under reduced pressure. The muraymycin analogues 12
(10 mg, 57%) and 13 (3.3 mg, 19%) were separated by preparative HPLC (12: tR = 17.8 min, 13: tR =
16.4 min) and obtained as colourless solids. 12: 1H NMR (600 MHz, D2O, 35 ◦C): δ [ppm] = 0.99 (d, J =
5.8 Hz, 3H, 5′ ′ ′-Ha), 1.04 (d, J = 5.4 Hz, 3H, 5′ ′ ′-Hb), 1.05 (d, J = 6.7 Hz, 3H, 4′ ′ ′ ′ ′-Ha), 1.08 (d, J = 6.8 Hz,
3H, 4′ ′ ′ ′ ′-Hb), 1.51–1.61 (m, 2H, 4′ ′ ′ ′-H), 1.66–1.84 (m, 6H, 3′ ′ ′-H, 4′ ′ ′-H, 3′ ′ ′ ′-Ha, 5′ ′ ′ ′-H), 1.88–1.94 (m,
1H, 3′ ′ ′ ′-Hb), 1.96–2.04 (m, 2H, 2′ ′-H), 2.26 (dqq, J = 6.8, 6.7, 6.1 Hz, 1H, 3′ ′ ′ ′ ′-H), 2.47 (ddd, J = 15.5,
10.1, 4.8 Hz, 1H, 5′-Ha), 2.59 (ddd, J = 15.5, 5.3, 2.9 Hz, 1H, 5′-Hb), 3.12 (dd, J = 7.6, 7.5 Hz, 2H, 6′ ′ ′ ′-H),
3.16 (ddd, J = 12.2, 8.8, 7.6 Hz, 1H, 1′ ′-Ha), 3.21 (ddd, J = 12.2, 8.6, 7.3 Hz, 1H, 1′ ′-Hb), 3.35 (ddd, J =
14.3, 8.0, 6.7 Hz, 1H, 3′ ′-Ha), 3.40 (ddd, J = 14.3, 7.5, 6.8 Hz, 1H, 3′ ′-Hb), 4.08 (dd, J = 5.3, 4.8 Hz, 1H,
6′-H), 4.16 (ddd, J = 10.1, 7.9, 2.9 Hz, 1H, 4′-H), 4.21–4.25 (m, 3H, 3′-H, 2′ ′ ′ ′-H, 2′ ′ ′ ′ ′-H), 4.37 (dd, J = 9.7,
4.7 Hz, 1H, 2′ ′ ′-H), 4.56 (dd, J = 5.6, 3.8 Hz, 1H, 2′-H), 5.84 (d, J = 3.8 Hz, 1H, 1′-H), 6.00 (d, J = 8.1 Hz,
1H, 5-H), 7.78 (d, J = 8.1 Hz, 1H, 6-H). 13C NMR (126 MHz, D2O, 35 ◦C): δ [ppm] = 19.68 (Ca-4′ ′ ′ ′ ′),
21.18 (Cb-4′ ′ ′ ′ ′), 23.37 (Ca-5′ ′ ′), 24.73 (C-4′ ′ ′ ′), 24.79 (Cb-5′ ′ ′), 27.09 (C-4′ ′ ′), 28.21 (C-2′ ′), 28.94 (C-5′ ′ ′ ′),
32.66 (C-3′ ′ ′ ′ ′), 33.42 (C-3′ ′ ′ ′), 34.63 (C-5′), 38.65 (C-3′ ′), 41.92 (C-6′ ′ ′ ′), 42.23 (C-3′ ′ ′), 47.29 (C-1′ ′), 55.21
(C-2′ ′ ′), 56.77 (C-2′ ′ ′ ′), 61.51 (C-2′ ′ ′ ′ ′), 62.56 (C-6′), 75.00 (C-2′), 75.39 (C-3′), 82.26 (C-4′), 94.93 (C-1′),
104.85 (C-5), 118.93 (q, 1JCF = 292.3 Hz, TFA-CF3), 145.71 (C-6), 153.92 (C-2), 161.94 (NC(=O)N), 165.37
(q, 2JCF = 35.3 Hz, TFA-COO), 168.53 (C-4), 174.09 (C-7′), 177.31 (C-1′ ′ ′), 177.82 (C-1′ ′ ′ ′), 179.08 (C-1′ ′ ′ ′ ′).
19F NMR (282 MHz, D2O, 35 ◦C): δ [ppm] = −72.86 (TFA-CF3). MS (ESI+): m/z = 743.5 [M + H]+.
HRMS (ESI+): calcd.: 743.3934 [M + H]+, found: 743.3926. IR (ATR): ν [cm−1] = 1633, 1551, 1198, 1182,
1131, 1054, 799, 720, 551. UV (H2O): λmax (log ε) = 261 (4.00). Optical rotation: [α]D25 = −3.8 (c = 0.45,
H2O). m.p. = 208 ◦C. 13: 1H NMR (600 MHz, D2O, 35 ◦C): δ [ppm] = 0.99 (d, J = 5.6 Hz, 3H, 5′ ′ ′-Ha),
1.05 (d, J = 6.1 Hz, 3H, 5′ ′ ′-Hb), 1.05 (d, J = 7.1 Hz, 3H, 4′ ′ ′ ′ ′-Ha), 1.08 (d, J = 6.6 Hz, 3H, 4′ ′ ′ ′ ′-Hb),
1.49–1.63 (m, 2H, 4′ ′ ′ ′-H), 1.68–1.93 (m, 7H, 3′ ′ ′-H, 4′ ′ ′-H, 3′ ′ ′ ′-H, 5′ ′ ′ ′-H), 1.97–2.02 (m, 2H, 2′ ′-H), 2.27
(dqq, J = 7.1, 6.6, 5.8 Hz, 1H, 3′ ′ ′ ′ ′-H), 2.47 (ddd, J = 15.3, 10.1, 4.7 Hz, 1H, 5′-Ha), 2.59 (ddd, J = 15.3,
5.3, 2.8 Hz, 1H, 5′-Hb), 3.11 (dd, J = 8.0, 7.8 Hz, 2H, 6′ ′ ′ ′-H), 3.14 (ddd, J = 12.7, 7.7, 7.3 Hz, 1H, 1′ ′-Ha),
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3.20 (ddd, J = 12.3, 7.2, 7.0 Hz, 1H, 1′ ′-Hb), 3.38 (dd, J = 6.7, 6.6 Hz, 2H, 3′ ′-H), 4.03 (dd, J = 5.3, 4.7 Hz,
1H, 6′-H), 4.16 (ddd, J = 10.1, 7.1, 2.8 Hz, 1H, 4′-H), 4.18 (d, J = 5.8 Hz, 1H, 2′ ′ ′ ′ ′-H), 4.24 (dd, J = 9.2,
6.3 Hz, 1H, 3′-H), 4.24 (dd, J = 5.9, 2.1 Hz, 1H, 2′ ′ ′ ′-H), 4.36 (dd, J = 10.3, 4.0 Hz, 1H, 2′ ′ ′-H), 4.55 (dd, J
= 9.2, 3.8 Hz, 1H, 2′-H), 5.85 (d, J = 3.8 Hz, 1H, 1′-H), 6.00 (d, J = 8.1 Hz, 1H, 5-H), 7.79 (d, J = 8.1 Hz,
1H, 6-H). 13C NMR (126 MHz, D2O, 35 ◦C): δ [ppm] = 19.72 (Ca -4′ ′ ′ ′ ′), 21.19 (Cb-4′ ′ ′ ′ ′), 23.00 (Ca-5′ ′ ′),
24.79 (C-4′ ′ ′ ′), 24.93 (Cb-5′ ′ ′), 27.14 (C-4′ ′ ′), 28.28 (C-2′ ′), 28.94 (C-5′ ′ ′ ′), 32.61 (C-3′ ′ ′ ′ ′), 33.48 (C-3′ ′ ′ ′),
34.72 (C-5′), 38.58 (C-3′ ′), 41.90 (C-6′ ′ ′ ′), 42.16 (C-3′ ′ ′), 47.30 (C-1′ ′), 55.21 (C-2′ ′ ′), 56.87 (C-2′ ′ ′ ′), 61.63
(C-2′ ′ ′ ′ ′), 62.96 (C-6′), 75.00 (C-2′), 75.41 (C-3′), 82.35 (C-4′), 94.78 (C-1′), 104.88 (C-5), 118.94 (q, 1JCF =
291.1 Hz, TFA-CF3), 145.67 (C-6), 153.96 (C-2), 161.81 (NC(=O)N), 165.40 (q, 2JCF = 35.3 Hz, TFA-COO),
168.55 (C-4), 174.33 (C-7′), 177.55 (C-1′ ′ ′), 178.10 (C-1′ ′ ′ ′), 179.23 (C-1′ ′ ′ ′ ′). 19F NMR (282 MHz, D2O,
35 ◦C): δ [ppm] = −72.87 (TFA-CF3). MS (ESI+): m/z = 743.5 [M + H]+. HRMS (ESI+): calcd.: 743.3934
[M + H]+, found: 743.3928. IR (ATR): ν [cm−1] = 1633, 1552, 1198, 1181, 1130, 1053, 720, 550, 518. UV
(H2O): λmax (log ε) = 260 (4.01). Optical rotation: [α]D25 = +28.7 (c = 0.15, H2O). m.p. = 209 ◦C.
6′-epi-L-Leu muraymycin analogue (14) and 6′-epi-D-Leu muraymycin analogue (15): To a solution
of the urea tripeptide 18 (13 mg, 0.024 mmol) in THF (3 mL), HOBt (3.2 mg, 0.024 mmol), EDC (4.6 mg,
0.024 mmol), and DIPEA (4.2 µL, 0.024 mmol) were added and the mixture was stirred at room
temperature for 45 min. It was then added to a solution of amine 21 (20 mg, 0.030 mmol) in THF (2 mL)
and stirred at room temperature for 18 h. EtOAc (30 mL) was added and the solution was washed with
sat. NaHCO3 (30 mL). The organic layer was dried over Na2SO4 and the solvent was removed under
reduced pressure. The protected analogues of 14 and 15 were obtained after column chromatography
(98:2–96:4, CH2Cl2-MeOH) as colourless solids. This material was dissolved in TFA (80% in water,
3.6 mL) and stirred at room temperature for 24 h. Water (10 mL) was added and the solvent was
removed under reduced pressure. The muraymycin analogues 14 (14 mg, 59%) and 15 (5.6 mg, 24%)
were separated by preparative HPLC (14: tR = 17.5 min, 15: tR = 16.1 min) and obtained as colourless
solids. 14: 1H NMR (600 MHz, D2O, 35 ◦C): δ [ppm] = 0.99 (d, J = 5.8 Hz, 3H, 5′ ′ ′-Ha), 1.04 (d, J =
5.7 Hz, 3H, 5′ ′ ′-Hb), 1.05 (d, J = 6.6 Hz, 3H, 4′ ′ ′ ′ ′-Ha), 1.09 (d, J = 6.8 Hz, 3H, 4′ ′ ′ ′ ′-Hb), 1.51–1.60 (m,
2H, 4′ ′ ′ ′-H), 1.66–1.85 (m, 6H, 3′ ′ ′-H, 4′ ′ ′-H, 3′ ′ ′ ′-Ha, 5′ ′ ′ ′-H), 1.89–1.94 (m, 1H, 3′ ′ ′ ′-Hb), 2.04 (dddd, J
= 7.4, 7.3, 6.7, 6.5 Hz, 2H, 2′ ′-H), 2.28 (dqq, J = 6.8, 6.6, 6.4 Hz, 1H, 3′ ′ ′ ′ ′-H), 3.12 (dd, J = 7.7, 7.6 Hz,
2H, 6′ ′ ′ ′-H), 3.18 (ddd, J = 12.9, 7.4, 7.3 Hz, 1H, 1′ ′-Ha), 3.25 (ddd, J = 12.9, 7.4, 7.3 Hz, 1H, 1′ ′-Hb), 3.38
(ddd, J = 14.3, 6.5, 6.5 Hz, 1H, 3′ ′-Ha), 3.45 (ddd, J = 14.3, 6.7, 6.7 Hz, 1H, 3′ ′-Hb), 4.10 (d, J = 4.5 Hz,
1H, 6′-H), 4.22–4.25 (m, 3H, 4′-H, 2′ ′ ′ ′-H, 2′ ′ ′ ′ ′-H), 4.37 (dd, J = 9.6, 4.9 Hz, 1H, 2′ ′ ′-H), 4.46 (dd, J = 5.8,
5.3 Hz, 1H, 3′-H), 4.48 (dd, J = 5.3, 4.0 Hz, 1H, 2′-H), 4.58 (dd, J = 4.5, 1.1 Hz, 1H, 5′-H), 5.99 (d, J =
8.1 Hz, 1H, 5-H), 6.00 (d, J = 4.0 Hz, 1H, 1′-H), 8.14 (d, J = 8.1 Hz, 1H, 6-H). 13C NMR (126 MHz, D2O,
35 ◦C): δ [ppm] = 19.69 (Ca-4′ ′ ′ ′ ′), 21.18 (Cb-4′ ′ ′ ′ ′), 23.33 (Ca-5′ ′ ′), 24.72 (C-4′ ′ ′ ′), 24.80 (Cb-5′ ′ ′), 27.08
(C-4′ ′ ′), 27.81 (C-2′ ′), 28.93 (C-5′ ′ ′ ′), 32.69 (C-3′ ′ ′ ′ ′), 33.35 (C-3′ ′ ′ ′), 38.32 (C-3′ ′), 41.92 (C-6′ ′ ′ ′), 42.15
(C-3′ ′ ′), 48.22 (C-1′ ′), 55.23 (C-2′ ′ ′), 56.87 (C-2′ ′ ′ ′), 61.51 (C-2′ ′ ′ ′ ′), 68.51 (C-6′), 69.43 (C-5′), 72.48 (C-3′),
75.64 (C-2′), 85.67 (C-4′), 92.87 (C-1′), 104.74 (C-5), 118.93 (q, 1JCF = 292.3 Hz, TFA-CF3), 145.06 (C-6),
154.07 (C-2), 161.96 (NC(=O)N), 165.37 (q, 2JCF = 35.3 Hz, TFA-COO), 168.55 (C-4), 172.02 (C-7′), 177.43
(C-1′ ′ ′), 177.93 (C-1′ ′ ′ ′), 179.06 (C-1′ ′ ′ ′ ′). 19F NMR (282 MHz, D2O, 35 ◦C): δ [ppm] = −72.86 (TFA-CF3).
MS (ESI+): m/z = 759.5 [M + H]+. HRMS (ESI+): calcd.: 759.3883 [M + H]+, found: 759.3886. IR (ATR):
ν [cm-1] = 1632, 1549, 1198, 1182, 1128, 1049, 720, 560, 520. UV (H2O): λmax (log ε) = 262 (3.94). Optical
rotation: [α]D25 = +5.4 (c = 0.54, H2O). m.p. = 215 ◦C. 15: 1H NMR (600 MHz, D2O, 35 ◦C): δ [ppm]
= 0.98 (d, J = 5.3 Hz, 3H, 5′ ′ ′-Ha), 1.04 (d, J = 5.3 Hz, 3H, 5′ ′ ′-Hb), 1.04 (d, J = 6.5 Hz, 3H, 4′ ′ ′ ′ ′-Ha),
1.08 (d, J = 6.8 Hz, 3H, 4′ ′ ′ ′ ′-Hb), 1.49–1.54 (m, 1H, 4′ ′ ′ ′-Ha), 1.56–1.62 (m, 1H, 4′ ′ ′ ′-Hb), 1.66–1.92 (m,
7H, 3′ ′ ′-H, 4′ ′ ′-H, 3′ ′ ′ ′-H, 5′ ′ ′ ′-H), 1.98–2.07 (m, 2H, 2′ ′-H), 2.27 (dqq, J = 6.8, 6.5, 4.8 Hz, 1H, 3′ ′ ′ ′ ′-H),
3.11 (dd, J = 7.6, 7.6 Hz, 2H, 6′ ′ ′ ′-H), 3.18 (ddd, J = 13.7, 7.1, 6.0 Hz, 1H, 1′ ′-Ha), 3.24 (ddd, J = 13.7,
7.3, 7.2 Hz, 1H, 1′ ′-Hb), 3.37–3.43 (m, 2H, 3′ ′-H), 4.14 (d, J = 5.4 Hz, 1H, 6′-H), 4.19 (d, J = 4.8 Hz, 1H,
2′ ′ ′ ′ ′-H), 4.22 (dd, J = 6.1, 4.9 Hz, 1H, 2′ ′ ′ ′-H), 4.23 (dd, J = 5.8, 1.8 Hz, 1H, 4′-H), 4.35 (dd, J = 10.3,
4.1 Hz, 1H, 2′ ′ ′-H), 4.45 (dd, J = 5.8, 5.3 Hz, 1H, 3′-H), 4.48 (dd, J = 5.3, 4.1 Hz, 1H, 2′-H), 4.58 (dd, J =
5.4, 1.8 Hz, 1H, 5′-H), 5.98 (d, J = 8.1 Hz, 1H, 5-H), 5.99 (d, J = 4.1 Hz, 1H, 1′-H), 8.12 (d, J = 8.1 Hz,
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1H, 6-H). 13C NMR (126 MHz, D2O, 35 ◦C): δ [ppm] = 19.69 (Ca-4′ ′ ′ ′ ′), 21.18 (Cb-4′ ′ ′ ′ ′), 23.00 (Ca-5′ ′ ′),
24.79 (C-4′ ′ ′ ′), 24.93 (Cb-5′ ′ ′), 27.13 (C-4′ ′ ′), 27.87 (C-2′ ′), 28.94 (C-5′ ′ ′ ′), 32.61 (C-3′ ′ ′ ′ ′), 33.47 (C-3′ ′ ′ ′),
38.23 (C-3′ ′), 41.90 (C-6′ ′ ′ ′), 42.14 (C-3′ ′ ′), 48.20 (C-1′ ′), 55.22 (C-2′ ′ ′), 56.88 (C-2′ ′ ′ ′), 61.53 (C-2′ ′ ′ ′ ′), 68.51
(C-6′), 69.43 (C-5′), 72.51 (C-3′), 75.58 (C-2′), 85.77 (C-4′), 92.84 (C-1′), 104.79 (C-5), 118.93 (q, 1JCF =
292.3 Hz, TFA-CF3), 145.10 (C-6), 154.12 (C-2), 161.80 (NC(=O)N), 165.39 (q, 2JCF = 36.5 Hz, TFA-COO),
168.57 (C-4), 171.97 (C-7′), 177.63 (C-1′ ′ ′), 178.09 (C-1′ ′ ′ ′), 179.16 (C-1′ ′ ′ ′ ′). 19F NMR (282 MHz, D2O,
35 ◦C): δ [ppm] = −72.87 (TFA-CF3). MS (ESI+): m/z = 759.5 [M + H]+. HRMS (ESI+): calcd.: 759.3883
[M+H]+, found: 759.3884. IR (ATR): ν [cm−1] = 1686, 1637, 1552, 1200, 1131, 721, 636, 568, 554. UV
(H2O): λmax (log ε) = 261 (4.08). Optical rotation: [α]D25 = +84.5 (c = 0.22, H2O). m.p. = 210 ◦C.
5′-epi-L-Leu muraymycin analogue (16) and 5′-epi-D-Leu muraymycin analogue (17): To a solution
of the urea tripeptide 18 (6.7 mg, 0.012 mmol) in THF (1.5 mL), HOBt (1.6 mg, 0.012 mmol), ECD
(2.3 mg, 0.012 mmol), and DIPEA (2.1 µL, 0.012 mmol) were added and the mixture was stirred at
room temperature for 45 min. It was then added to a solution of amine 22 (10 mg, 0.015 mmol) in
THF (3 mL) and stirred at room temperature for 18 h. EtOAc (30 mL) was added and the solution was
washed with sat. NaHCO3 (30 mL). The organic layer was dried over Na2SO4 and the solvent was
removed under reduced pressure. The protected analogues of 16 and 17 were obtained after column
chromatography (98:2–96:4, CH2Cl2-MeOH) as colourless solids. This material was dissolved in TFA
(80% in water, 1.8 mL) and stirred at room temperature for 24 h. Water (10 mL) was added and the
solvent was removed under reduced pressure. The muraymycin analogues 16 (6.4 mg, 54%) and 17
(3.2 mg, 27%) were separated by preparative HPLC (16: tR = 17.9 min, 17: tR = 16.3 min) and obtained
as colourless solids. 16: 1H NMR (600 MHz, D2O, 35 ◦C): δ [ppm] = 0.98 (d, J = 5.7 Hz, 3H, 5′ ′ ′-Ha), 1.03
(d, J = 5.5 Hz, 3H, 5′ ′ ′-Hb), 1.04 (d, J = 6.4 Hz, 3H, 4′ ′ ′ ′ ′-Ha), 1.08 (d, J = 7.0 Hz, 3H, 4′ ′ ′ ′ ′-Hb), 1.50–1.60
(m, 2H, 4′ ′ ′ ′-H), 1.66–1.83 (m, 6H, 3′ ′ ′-H, 4′ ′ ′-H, 3′ ′ ′ ′-Ha, 5′ ′ ′ ′-H), 1.87–1.93 (m, 1H, 3′ ′ ′ ′-Hb), 2.07 (dddd,
J = 7.7, 7.6, 6.6, 6.5 Hz, 2H, 2′ ′-H), 2.28 (dqq, J = 7.0, 6.4, 5.7 Hz, 1H, 3′ ′ ′ ′ ′-H), 3.11 (dd, J = 7.7, 7.7 Hz, 2H,
6′ ′ ′ ′-H), 3.25 (dd, J = 7.7, 7.6 Hz, 2H, 1′ ′-H), 3.39 (ddd, J = 14.2, 6.6, 6.5 Hz, 1H, 3′ ′-Ha), 3.48 (ddd, J =
14.2, 6.6, 6.5 Hz, 1H, 3′ ′-Hb), 4.14 (d, J = 2.9 Hz, 1H, 6′-H), 4.22 (d, J = 5.7 Hz, 1H, 2′ ′ ′ ′ ′-H), 4.24 (dd, J =
8.7, 5.5 Hz, 1H, 2′ ′ ′ ′-H), 4.30 (dd, J = 8.4, 3.5 Hz, 1H, 4′-H), 4.39 (dd, J = 9.5, 4.7 Hz, 1H, 2′ ′ ′-H), 4.46 (dd,
J = 8.4, 2.9 Hz, 1H, 5′-H), 4.49 (dd, J = 5.5, 3.5 Hz, 1H, 3′-H), 4.74 (dd, J = 5.9, 5.5 Hz, 1H, 2′-H), 5.84 (d, J
= 5.9 Hz, 1H, 1′-H), 6.00 (d, J = 8.0 Hz, 1H, 5-H), 7.78 (d, J = 8.0 Hz, 1H, 6-H). 13C NMR (126 MHz, D2O,
35 ◦C): δ [ppm] = 19.68 (Ca-4′ ′ ′ ′ ′), 21.18 (Cb-4′ ′ ′ ′ ′), 23.39 (Ca-5′ ′ ′), 24.69 (C-4′ ′ ′ ′), 24.76 (Cb-5′ ′ ′), 27.09
(C-4′ ′ ′), 28.12 (C-2′ ′), 28.93 (C-5′ ′ ′ ′), 32.66 (C-3′ ′ ′ ′ ′), 33.45 (C-3′ ′ ′ ′), 38.74 (C-3′ ′), 41.92 (C-6′ ′ ′ ′), 42.23
(C-3′ ′ ′), 47.50 (C-1′ ′), 55.25 (C-2′ ′ ′), 56.73 (C-2′ ′ ′ ′), 61.48 (C-2′ ′ ′ ′ ′), 65.70 (C-6′), 71.73 (C-5′), 73.67 (C-3′),
74.33 (C-2′), 86.08 (C-4′), 94.17 (C-1′), 104.86 (C-5), 118.93 (q, 1JCF = 291.1 Hz, TFA-CF3), 146.11 (C-6),
153.90 (C-2), 161.92 (NC(=O)N), 165.38 (q, 2JCF = 35.3 Hz, TFA-COO), 168.59 (C-4), 171.19 (C-7′), 177.37
(C-1′ ′ ′), 177.76 (C-1′ ′ ′ ′), 179.05 (C-1′ ′ ′ ′ ′). 19F NMR (282 MHz, D2O, 35 ◦C): δ [ppm] = −72.88 (TFA-CF3).
MS (ESI+): m/z = 759.5 [M + H]+. HRMS (ESI+): calcd.: 759.3883 [M + H]+, found: 759.3884. IR (ATR):
ν [cm−1] = 1660, 1633, 1551, 1197, 1184, 1132, 720, 547, 511. UV (H2O): λmax (log ε) = 260 (3.98). Optical
rotation: [α]D25 = -10.6 (c = 0.16, H2O). m.p. = 214 ◦C. 17: 1H NMR (600 MHz, D2O, 35 ◦C): δ [ppm] =
0.98 (d, J = 5.3 Hz, 3H, 5′ ′ ′-Ha), 1.00 (d, J = 6.8 Hz, 3H, 5′ ′ ′-Hb), 1.04 (d, J = 6.0 Hz, 3H, 4′ ′ ′ ′ ′-Ha), 1.05 (d,
J = 6.8 Hz, 3H, 4′ ′ ′ ′ ′-Hb), 1.51–1.63 (m, 2H, 4′ ′ ′ ′-H), 1.69–1.87 (m, 6H, 3′ ′ ′-H, 4′ ′ ′-H, 3′ ′ ′ ′-Ha, 5′ ′ ′ ′-H),
1.88–1.94 (m, 1H, 3′ ′ ′ ′-Hb), 2.07 (dddd, J = 7.3, 7.2, 6.6, 6.3 Hz, 2H, 2′ ′-H), 2.21 (dqq, J = 6.8, 6.0, 5.9 Hz,
1H, 3′ ′ ′ ′ ′-H), 3.12 (dd, J = 7.6, 7.4 Hz, 2H, 6′ ′ ′ ′-H), 3.20–3.26 (m, 2H, 1′ ′-H), 3.39 (ddd, J = 14.3, 6.6,
6.3 Hz, 1H, 3′ ′-Ha), 3.47 (ddd, J = 14.3, 6.6, 6.3 Hz, 1H, 3′ ′-Hb), 3.95 (d, J = 3.0 Hz, 1H, 6′-H), 4.06 (d, J =
5.9 Hz, 1H, 2′ ′ ′ ′ ′-H), 4.23 (dd, J = 7.3, 7.1 Hz, 1H, 2′ ′ ′ ′-H), 4.29 (dd, J = 7.6, 4.4 Hz, 1H, 4′-H), 4.38 (dd, J
= 9.5, 4.1 Hz, 1H, 2′ ′ ′-H), 4.44 (dd, J = 7.6, 3.0 Hz, 1H, 5′-H), 4.49 (dd, J = 5.3, 4.4 Hz, 1H, 3′-H), 4.65 (dd,
J = 5.6, 5.3 Hz, 1H, 2′-H), 5.89 (d, J = 5.6 Hz, 1H, 1′-H), 6.01 (d, J = 8.1 Hz, 1H, 5-H), 7.83 (d, J = 8.1 Hz,
1H, 6-H). 13C NMR (126 MHz, D2O, 35 ◦C): δ [ppm] = 19.77 (Ca-4′ ′ ′ ′ ′), 21.56 (Cb-4′ ′ ′ ′ ′), 22.98 (Ca-5′ ′ ′),
24.79 (C-4′ ′ ′ ′), 24.95 (Cb-5′ ′ ′), 27.12 (C-4′ ′ ′), 28.13 (C-2′ ′), 28.98 (C-5′ ′ ′ ′), 33.04 (C-3′ ′ ′ ′ ′), 33.38 (C-3′ ′ ′ ′),
38.77 (C-3′ ′), 41.92 (C-6′ ′ ′ ′), 42.17 (C-3′ ′ ′), 47.46 (C-1′ ′), 55.19 (C-2′ ′ ′), 56.84 (C-2′ ′ ′ ′), 63.09 (C-2′ ′ ′ ′ ′), 66.68
(C-6′), 71.79 (C-5′), 73.11 (C-3′), 74.83 (C-2′), 86.09 (C-4′), 94.45 (C-1′), 104.88 (C-5), 118.89 (q, 1JCF =
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291.1 Hz, TFA-CF3), 145.66 (C-6), 154.01 (C-2), 161.81 (NC(=O)N), 165.39 (q, 2JCF = 37.8 Hz, TFA-COO),
168.63 (C-4), 171.91 (C-7′), 177.01 (C-1′ ′ ′), 177.54 (C-1′ ′ ′ ′), 178.33 (C-1′ ′ ′ ′ ′). 19F NMR (282 MHz, D2O,
35 ◦C): δ [ppm] = –72.88 (TFA-CF3). MS (ESI+): m/z = 759.5 [M + H]+. HRMS (ESI+): calcd.: 759.3883
[M + H]+, found: 759.3888. IR (ATR): ν [cm−1] = 1667, 1634, 1552, 1201, 1132, 1056, 800, 721, 547. UV
(H2O): λmax (log ε) = 260 (3.95). optical rotation: [α]D25 = +13.1 (c = 0.13, H2O). m.p. = 218 ◦C.
Protected urea tripeptide (18): To a solution of 29 (50 mg, 0.076 mmol) in THF (4 mL),
tetrabutylammonium fluoride (TBAF, 1 M in THF, 91 µL, 0.091 mmol) was added at 0 ◦C and the
mixture was stirred at 0 ◦C for 1 h. More TBAF (1 M in THF, 30 µL, 0.030 mmol) was added and the
mixture was stirred at room temperature for 3 h. The solvent was removed under reduced pressure.
The urea tripeptide 18 was obtained after column chromatography (95:4:1, CH2Cl2-MeOH-HOAc) as
colourless solid (39 mg, 92%). 1H NMR (600 MHz, DMSO-d6, 35 ◦C): δ [ppm] = 0.83 (d, J = 6.9 Hz, 3H,
4-Ha), 0.83 (d, J = 6.5 Hz, 3H, 5′ ′-Ha), 0.85 (d, J = 6.8 Hz, 3H, 4-Hb), 0.88 (d, J = 6.6 Hz, 3H, 5′ ′-Hb),
1.22–1.28 (m, 2 H, 4′-H), 1.35–1.44 (m, 3H, 3′-Ha, 5′ ′-H), 1.38 (s, 9H, OC(CH3)3), 1.40 (s, 9H, OC(CH3)3),
1.52 (ddd, J = 9.1, 5.3, 5.0 Hz, 2H, 3′ ′-H), 1.53–1.58 (m, 1H, 3′-Hb), 1.57.1.65 (m, 1H, 4′ ′-H), 1.96 (dqq, J
= 6.9, 6.8, 5.1 Hz, 1H, 3-H), 2.84–2.88 (m, 2H, 6′-NH), 3.92 (dd, J = 8.6, 5.1 Hz, 1H, 2-H), 4.14 (ddd, J
= 8.2, 7.7, 5.3 Hz, 1H, 2′-H), 4.20 (ddd, J = 9.1, 8.0, 5.6 Hz, 1H, 2′ ′-H), 6.25 (d, J = 8.6 Hz, 1H, 2-NH),
6.27 (d, J = 7.7 Hz, 1H, 2′-NH), 6.66 (dd, J = 6.0, 5.8 Hz, 1H, 6′-NH), 8.01 (d, J = 8.0 Hz, 1H, 2′ ′-NH).
13C NMR (126 MHz, DMSO-d6, 35 ◦C): δ [ppm] = 17.59 (Ca-4), 18.92 (Cb-4), 21.33 (Ca-5′ ′), 22.24 (C-4′),
24.79 (Cb-5′ ′), 24.17 (C-4′ ′), 27.64 (OC(CH3)3), 28.20 (OC(CH3)3), 29.30 (C-5′), 30.43 (C-3), 32.97 (C-3′),
39.76 (C-6′), 39.92 (C-3′ ′), 50.09 (C-2′ ′), 52.41 (C-2′), 58.10 (C-2), 77.13 (OC(CH3)3), 80.04 (OC(CH3)3),
155.25 (NC(=O)O), 157.09 (NC(=O)N), 171.36 (C-1), 172.09 (C-1′), 173.64 (C-1′ ′). MS (ESI+): m/z = 581.3
[M + Na]+. HRMS (ESI+): calcd.: 581.3521 [M + Na]+, found: 581.3522. IR (ATR): ν [cm−1] = 1719, 1688,
1633, 1546, 1391, 1366, 1250, 1156, 665. Optical rotation: [α]D25 = −3.3 (c = 0.24, CHCl3). m.p. = 73 ◦C.
TLC: Rf = 0.25 (94:5:1, CH2Cl2-MeOH-AcOH).
6′-epi nucleoside building block (21): To a solution of 33 (45 mg, 0.057 mmol) in MeOH (4 mL),
Pd/C (10%, 10 mg, 9.4 µmol) and 1,4-cyclohexadiene (54 µL, 0.57 mmol) were added and the mixture
was stirred at room temperature for 2 h. More Pd/C (10%, 5 mg, 5 µmol) and 1,4-cyclohexadiene
(54 µL, 0.57 mmol) were added and the mixture was stirred at room temperature for 1 h. The mixture
was filtered and the residue was washed with MeOH (3 × 4 mL). The solvent of the combined filtrates
was removed under reduced pressure to give 21 as a colourless solid (37 mg, 99%). 1H NMR (600 MHz,
CD3OD): δ [ppm] = 0.05 (s, 3H, SiCH3), 0.07 (s, 3H, SiCH3), 0.12 (s, 3H, SiCH3), 0.14 (s, 3H, SiCH3), 0.88
(s, 9H, SiC(CH3)3), 0.94 (s, 9H, SiC(CH3)3), 1.49 (s, 9H, OC(CH3)3), 1.66–1.75 (m, 2H, 2′ ′-H), 2.63 (ddd, J
= 12.3, 6.2, 5.9 Hz, 1H, 1′ ′-Ha), 2.76 (ddd, J = 12.3, 7.2, 5.6 Hz, 1H, 1′ ′-Hb), 2.94–2.96 (m, 2H, 3′ ′-H), 3.38
(d, J = 7.4 Hz, 1 H, 6′-H), 3.87 (dd, J = 7.4, 1.2 Hz, 1H, 5′-H), 4.17 (dd, J = 4.2, 3.7 Hz, 1H, 3′-H), 4.20 (dd,
J = 3.7, 1.2 Hz, 1H, 4′-H), 4.36 (dd, J = 5.3, 4.2 Hz, 1H, 2′-H), 5.72 (d, J = 8.1 Hz, 1H, 5-H), 5.88 (d, J =
5.3 Hz, 1H, 1′-H), 8.18 (d, J = 8.1 Hz, 1H, 6-H). 13C NMR (126 MHz, CD3OD): δ [ppm] = −4.58 (SiCH3),
−4.49 (SiCH3), −4.49 (SiCH3), −4.22 (SiCH3), 18.76 (SiC(CH3)3), 18.85 (SiC(CH3)3), 26.24 (SiC(CH3)3),
26.31 (SiC(CH3)3), 28.29 (OC(CH3)3), 29.82 (C-2′ ′), 40.38 (C-3′ ′), 46.92 (C-1′ ′), 65.99 (C-6′), 71.28 (C-5′),
74.41 (C-3′), 76.01 (C-2′), 82.79 (OC(CH3)3), 86.15 (C-4′), 90.00 (C-1′), 102.72 (C-5), 142.68 (C-6), 152.45
(C-2), 166.11 (C-4), 174.08 (C-7′). MS (ESI+): m/z = 659.4 [M + H]+. HRMS (ESI+): calcd.: 659.3866 [M +
H]+, found: 659.3867. IR (ATR): ν [cm−1] = 1686, 1253, 1153, 1113, 1051, 869, 834, 812, 773. UV (MeOH):
λmax (log ε) = 207 (3.98), 262 (3.98). Optical rotation: [α]D25 = +24.0 (c = 0.30, MeOH). m.p. = 115 ◦C.
5′-epi nucleoside building block (22): To a solution of 34 (5.0 mg, 6.3 µmol) in MeOH (4 mL), Pd/C
(10%, 5 mg, 5 µmol), and 1,4-cyclohexadiene (6.3 µL, 0.063 mmol) were added and the mixture was
stirred at room temperature for 30 min. More Pd/C (10%, 5 mg, 5 µmol) was added and the mixture
was stirred at room temperature for 30 min. The mixture was filtered and the residue was washed
with MeOH (3 × 4 mL). The solvent of the combined filtrates was removed under reduced pressure to
give 22 as a colourless solid (4.1 mg, 99%). 1H NMR (600 MHz, pyridine-d5, 35 ◦C): δ [ppm] = 0.14 (s,
3H, SiCH3), 0.16 (s, 3H, SiCH3), 0.26 (s, 3H, SiCH3), 0.35 (s, 3H, SiCH3), 0.94 (s, 9H, SiC(CH3)3), 1.06
(s, 9H, SiC(CH3)3), 1.59 (s, 9H, OC(CH3)3), 2.11–2.16 (m, 1H, 2′ ′-Ha), 2.21–2.26 (m, 1H, 2′ ′-Hb), 3.09
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(ddd, J = 12.3, 7.2, 5.6 Hz, 1H, 1′ ′-Ha), 3.22 (ddd, J = 12.3, 6.1, 6.1 Hz, 1H, 1′ ′-Hb), 3.45 (ddd, J = 12.5, 6.8,
6.7 Hz, 1H, 3′ ′-Ha), 3.50 (ddd, J = 12.5, 6.6 Hz, 6.5 Hz, 1H, 3′ ′-Hb), 4.06 (d, J = 3.8 Hz, 1H, 6′-H), 4.68 (d,
J = 7.9 Hz, 1H, 4′-H), 4.79 (d, J = 4.3 Hz, 1H, 3′-H), 4.88 (dd, J = 7.9, 3.8 Hz, 1H, 5′-H), 5.12 (dd, J = 7.9,
4.3 Hz, 1H, 2′-H), 6.03 (d, J = 8.1 Hz, 1H, 5-H), 6.88 (d, J = 7.9 Hz, 1H, 1′-H), 8.41 (d, J = 8.1 Hz, 1H,
6-H). 13C NMR (126 MHz, pyridine-d5, 35 ◦C): δ [ppm] = −4.46 (SiCH3), −4.05 (SiCH3), −4.00 (SiCH3),
−3.95 (SiCH3), 18.32 (SiC(CH3)3), 18.51 (SiC(CH3)3), 26.16 (SiC(CH3)3), 26.26 (SiC(CH3)3), 27.75 (C-2′ ′),
28.41 (OC(CH3)3), 39.51 (C-3′ ′), 46.86 (C-1′ ′), 64.60 (C-6′), 73.58 (C-5′), 73.85 (C-2′), 74.03 (C-3′), 81.72
(OC(CH3)3), 87.19 (C-4′), 87.19 (C-1′), 103.29 (C-5), 142.71 (C-6), 152.37 (C-2), 164.15 (C-4), 171.56 (C-7′).
MS (ESI+): m/z = 659.4 [M + H]+. HRMS (ESI+): calcd.: 659.3866 [M + H]+, found: 659.3871. IR (ATR):
ν [cm−1] = 1678, 1252, 1155, 1057, 865, 833, 813, 776, 542. UV (MeOH): λmax (log ε) = 205 (3.98), 260
(3.84). Optical rotation: [α]D25 = −32.1 (c = 0.42, MeOH). m.p. = 184 ◦C.
Nε-tert-butyloxycarbonyl-L-lysine trimethylsilylethyl ester (24): To a solution of Nα-
benzyloxycarbonyl-Nε-tert-butyloxycarbonyl-L-lysine 23 (667 mg, 1.75 mmol), ECD (673 mg,
3.51 mmol), and 4-(dimethylamino)pyridine (DMAP, 175 mg, 1.43 mmol) in CH2Cl2 (8.9 mL),
2-(trimethylsilyl)ethanol (380 µL, 310 mg, 2.62 mmol) was added and the mixture was stirred at
room temperature for 25 h. It was then washed with sat. NaHCO3 (3 × 30 mL), brine (3 × 30 mL),
and water (60 mL). The organic layer was dried over Na2SO4 and the solvent was removed under
reduced pressure. The resultant crude product was purified by column chromatography (6:4, petroleum
ether-CH2Cl2) to give the Nα-protected lysine ester as a colourless oil (653 mg, 77%). This material
(600 mg, 1.25 mmol) was dissolved in MeOH (2 mL), Pd/C (10%, 190 mg, 0.179 mmol) was added and
the mixture was stirred under a hydrogen atmosphere (1 bar) at room temperature for 3 h. It was then
filtered over celiterTM, the residue was washed with MeOH and the solvent of the combined filtrates
was removed under reduced pressure to give 24 as a colourless oil (422 mg, 99%, 77% over 2 steps
from 23). 1H NMR (300 MHz, CD2Cl4, 100 ◦C): δ [ppm] = 4.53–4.44 (m, 1H, NεH), 4.26–4.20 (m, 2H,
H-1′), 3.39–3.35 (m, 1H, H-2), 3.14–3.07 (m, 2H, H-6), 1.80–1.68 (m, 1H, H-3a), 1.59–1.39 (m, 5H, H-3b,
H-4, H-5), 1.45 (s, 9H, Boc-CH3), 1.05–1.00 (m, 2H, H-2′), 0.08 (s, 9H, Si(CH3)3). 13C-NMR (75 MHz,
CD2Cl4, 100 ◦C): δ [ppm] = 175.38 (C-1), 155.57 (Boc-C=O), 78.67 (Boc-C), 62.70 (C-1′), 54.33 (C-2), 40.48
(C-6), 34.25 (C-3), 29.64 (C-5), 28.23 (Boc-CH3), 22.71 (C-4), 17.34 (C-2′), -1.77 (Si(CH3)3). MS (ESI+):
m/z = 347.2 [M + H]+. HRMS (ESI+): calcd.: 347.2361 [M + H]+, found: 347.2364. IR (ATR): ν [cm−1] =
3372, 2952, 2364, 1713, 1520, 1365, 1250, 1171, 838. Optical rotation: [α]D25 = +5.5 (c = 0.58, CHCl3).
TLC: Rf (95:5, CH2Cl2-MeOH) = 0.80.
Protected urea dipeptide trimethylsilylethyl ester (26): To a solution of 24 (10 mg, 29 µmol)
and N-(S-methylthiocarbonyl)-L-valine tert-butyl ester 25 (7.9 mg, 32 µmol) in EtOAc (1 mL),
N-methylmorpholine (NMM, 9.5 µL, 8.7 mg, 86 µmol) and silver(I)-trifluoromethanesulfonate (AgOTf,
11 mg, 43 µmol) were added and the mixture was stirred at room temperature for 17 h. The solvent
was removed under reduced pressure, and the resultant crude product was purified by column
chromatography (3:1, petroleum ether-EtOAc) to give 26 as colourless oil (12 mg, 76%). 1H NMR
(300 MHz, CD2Cl4, 100 ◦C): δ [ppm] = 4.98 (d, J = 8.0 Hz, 1H, Lys-NαH), 4.95 (d, J = 8.8 Hz, 1H, Val-NH),
4.63–4.48 (m, 1H, Lys-NεH), 4.38 (ddd, J = 8.0, 7.6, 5.5 Hz, 1H, Lys-H-2), 4.31–4.14 (m, 3H, Val-H-2,
H-1), 3.10 (dd, J = 13.0, 6.7 Hz, 2H, Lys-H-6), 2.18–2.03 (m, 1H, Val-H-3), 1.89–1.75 (m, 1H, Lys-H-3a),
1.75–1.59 (m, 1H, Lys-H-3b), 1.59–1.32 (m, 4H, Lys-H-4, Lys-H-5), 1.49 (s, 9H, t-Bu-CH3) 1.46 (s, 9H,
Boc-CH3), 1.08–0.99 (m, 2H, H-2), 0.97 (d, J = 9.5 Hz, 3H, Val-H-4), 0.94 (d, J = 9.5 Hz, 3H, Val-H-4), 0.08
(s, 9H, Si(CH3)3). 13C NMR (75 MHz, CD2Cl4, 100 ◦C): δ [ppm] = 172.89 (Lys-C-1), 171.56 (Val-C-1),
156.78 (Boc-C=O), 155.69 (urea-C=O), 81.42 (t-Bu-C), 78.71 (Boc-C), 63.24 (C-1), 58.68 (Val-C-2), 53.13
(Lys-C-2), 40.35 (Lys-C-6), 32.33 (Lys-C-3), 31.16 (Val-C-3), 29.46 (Lys-C-5), 28.26 (t-Bu-CH3), 27.90
(Boc-CH3), 22.35 (Lys-C-4), 18.55 (Val-C-4), 17.60 (Val-C-4), 17.32 (C-2), -1.80 (Si(CH3)3). MS (ESI+):
m/z = 568.3 [M + Na]+. HRMS (ESI)+: calcd.: 568.3388 [M + Na]+, found: 568.3391. IR (ATR): ν [cm−1]
= 3355, 2961, 1715, 1644, 1550, 1365, 1249, 1164, 836. Optical rotation: [α]D25 = 7.7 (c = 0.38, CHCl3).
TLC: Rf (3:2, petroleum ether-EtOAc) = 0.47.
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Protected urea dipeptide (27): To a solution of 26 (380 mg, 0.696 mmol) in THF (8.7 mL),
tetrabutylammoniumfluoride solution (TBAF, 1 M in THF, 840 µL, 0.840 mmol) was added at
0 ◦C and the mixture was stirred at room temperature for 5 h. The solvent was removed under
reduced pressure, and the resultant crude product was purified by column chromatography (95:5:1,
CH2Cl2-MeOH-HOAc) to give 27 as colourless oil (287 mg, 93%). 1H NMR (300 MHz, CD2Cl4, 100 ◦C):
δ [ppm] = 5.69–5.37 (m, 2H, Lys-NαH, Val-NαH). 4.95–4.83 (m, 1H, Lys-NεH), 4.36–4.28 (m, 1H,
Lys-H-2), 4.25–4.18 (m, 1H, Val-H-2), 3.16–3.06 (m, 2H, Lys-H-6), 2.23–2.02 (m, 1H, Val-H-3), 1.95–1.80
(m, 1H, Lys-H-3a), 1.80–1.66 (m, 1H, Lys-H-3b), 1.51–1.48 (m, 4H, Lys-H-4, Lys-H-5), 1.48 (s, 9H,
t-Bu-CH3) 1.47 (s, 9H, Boc-CH3), 0.97 (d, J = 10.5 Hz, 3H, Val-H-4), 0.94 (d, J = 10.5 Hz, 3H, Val-H-4).
13C NMR (75 MHz, CD2Cl4, 100 ◦C): δ [ppm] = 175.12 (Lys-C-1) 171.99 (Val-C-1), 158.34 (Boc-C=O),
156.21 (urea-C=O), 81.98 (t-Bu-C), 81.74 (Boc-C), 58.46 (Val-C-2), 53.38 (Lys-C-2), 40.04 (Lys-C-6), 31.16
(Lys-C-3), 31.11 (Val-C-3), 29.29 (Lys-C-5), 28.26 (t-Bu-CH3), 27.85 (Boc-CH3), 22.25 (Lys-C-4), 18.69
(Val-C-4), 17.43 (Val-C-4). MS (ESI+): m/z = 468.3 [M + Na]+. HRMS (ESI+): calcd.: 468.2680 [M + Na]+,
found: 468.2681. IR (ATR): ν [cm−1] = 3359, 2967, 1715, 1640, 1552, 1366, 1159, 847. Optical rotation:
[α]D25 = 19.9 (c = 0.80, CHCl3). TLC: Rf (7:3:1, CH2Cl2:MeOH:HOAc) = 0.41.
L-leucine trimethylsilylethyl ester trifluoroacetate (28): To a solution of
N-benzyloxycarbonyl-L-leucine 30 (10.0 g, 37.8 mmol) in CH2Cl2 (385 mL), EDC (9.21 g, 48 mmol),
DMAP (922 mg, 7.55 mmol), and 2-(trimethylsilyl)ethanol (6.87 mL, 5.67 g, 48.0 mmol) were added and
the mixture was stirred at room temperature for 14 h. It was then washed with HCl (1 M, 3 × 600 mL),
sat. NaHCO3 (3 × 600 mL), and brine (3 × 600 mL). The organic layer was dried over NaSO4 and the
solvent was removed under reduced pressure. N-benzyloxycarbonyl-L-leucine trimethylsilylethyl
ester was isolated after column chromatography as a colourless oil (11.8 g, 86%). To a solution of
this material (366 mg, 1.00 mmol) in MeOH (40 mL), TFA (80 µL, 0.12 g, 1.0 mmol) and Pd/C (10%,
146 mg, 0.130 mmol) were added and the mixture was stirred under hydrogen atmosphere (1 bar) at
room temperature for 4 h. It was then filtered over celite™ and the residue was washed with MeOH.
The solvent of the combined filtrates was removed under reduced pressure to give 28 as a colourless
solid (345 mg, quant., 86% over 2 steps from 30). 1H NMR (300 MHz, CDCl3): δ [ppm] = 4.29–4.23
(m, 2H, H-1′), 3.90 (dd, J = 7.0, 7.0 Hz, 1H, H-2), 1.87–1.73 (m, 3H, H-3, H-4), 1.05–0.99 (m, 2H, H-2′),
0.97 (d, J = 6.1 Hz, 3H, H-5), 0.95 (d, J = 6.1 Hz, 3H, H-5), 0.04 (s, 9H, Si(CH3)3). 13C NMR (75 MHz,
CDCl3): δ [ppm] = 170.12 (C-1), 162.73–161.77 (m, TFA-COO), 116.32–114.45 (m, TFA-CF3), 65.12 (C-1′),
51.54 (C-2), 39.61 (C-3), 24.29 (C-4), 22.09 (C-5), 21.74 (C-5), 17.19 (C-2′), −1.68 (Si(CH3)3). 19F NMR
(282 MHz, CDCl3): δ [ppm] = −75.98 (TFA-CF3). MS (ESI+): m/z = 232.2 [M − TFA]+. HRMS (ESI+):
calcd.: 232.1727 [M − TFA]+, found: 232.1724. IR (ATR): ν [cm−1] = 1733, 1665, 1250, 1201, 1174, 1137,
1042, 930, 834. Optical rotation: [α]D25 = 3.6 (c = 1.0, CHCl3). m.p. = 85 ◦C. TLC: Rf (9:1, petroleum
ether:EtOAc) = 0.76.
Protected urea tripeptide trimethylsilylethyl ester (29): To a solution of 27 (15 mg, 35 µmol) in
THF (1 mL), HOBt (4.7 mg, 35 µmol), and EDC (6.7 mg, 35 µmol) were added and the mixture was
stirred at room temperature for 30 min. A solution of 28 (12 mg, 35 µmol) and DIPEA (12 µL, 9.0 mg,
70 µmol) in CH2Cl2 (1 mL) was added and the mixture was stirred at room temperature for 18 h.
The solvent was removed under reduced pressure, and the resultant crude product was purified by
column chromatography (99:1, CH2Cl2-MeOH) to give 29 as a colourless solid (18 mg, 80%). 1H
NMR (300 MHz, CD2Cl4, 100 ◦C): δ [ppm] = 6.59 (d, J = 8.1 Hz, 1H, Lys-NαH), 5.21 (d, J = 7.8 Hz,
1H, Leu-NH), 5.14 (d, J = 8.7 Hz, 1H, Val-NH), 4.76–4.64 (m, 1H, Lys-NεH), 4.53 (ddd, J = 8.2, 8.1,
5.2 Hz, 1H, Lys-H-2), 4.31–4.12 (m, 4H, Val-H-2, Leu-H-2, H-1), 3.10 (dd, J = 13.1, 6.3 Hz, 2H, Lys-H-6),
2.20–2.02 (m, 1H, Val-H-3), 1.93–1.76 (m, 1H, Lys-H-3a), 1.77–1.34 (m, 8H, Lys-H-3b, Lys-H-4, Lys-H-5,
Leu-H-3, Leu-H-4), 1.46 (s, 9H, Boc-CH3), 1.49 (s, 9H, t-Bu-CH3), 1.10–1.00 (m, 2H, H-2), 1.01–0.87 (m,
12H, 2 × Val-H-4, 2 × Leu-H-5), 0.07 (s, 9H, Si(CH3)3). 13C NMR (75 MHz, CD2Cl4, 100 ◦C): δ [ppm]
= 172.41 (Lys-C-1), 172.36 (Val-C-1), 172.06 (Leu-C-1), 157.52 (Boc-C=O), 155.97 (urea-C=O), 81.55
(t-Bu-C), 78.78 (Boc-C), 63.24 (C-1), 58.34 (Val-C-2), 53.51 (Lys-C-2), 50.77 (Leu-C-2), 41.06 (Lys-C-6),
39.90 (Leu-C-3), 31.51 (Lys-C-3), 31.03 (Val-C-3), 29.47 (Lys-C-5), 28.29 (t-Bu-CH3), 27.88 (Boc-CH3),
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24.52 (Leu-C-4), 22.57 (Lys-C-4), 22.39 (Val-C-4), 21.79 (Val-C-4), 18.80 (Leu-C-5), 17.43 (Leu-C-5), 17.15
(C-2), −1.73 (Si(CH3)3). MS (ESI+): m/z = 681.50 [M + Na]+. HRMS (ESI+): calcd.: 681.4229 [M + Na]+,
found: 681.4233. IR (ATR): ν [cm−1] = 3339, 2958, 1731, 1688, 1633, 1546, 1249, 1153, 837. Optical
rotation: [α]D25 = −14.1 (c = 0.91, CHCl3). m.p. = 108 ◦C. TLC: Rf (98:2, CH2Cl2:MeOH) = 0.48.
Cbz-protected 6′-epi nucleoside building block (33): To a solution of the uridine-derived epoxy
tert-butyl ester 31 (60 mg, 0.10 mmol) in i-PrOH (4 mL), N-benzyloxycarbonyl-1,3-diaminopropane
32 (31 mg, 0.15 mmol) was added and the mixture was stirred under reflux for 4 d. The solvent
was removed under reduced pressure, and the resultant crude product was purified by column
chromatography (1:1, petroleum ether-EtOAc) to give 33 as a colourless solid (61 mg, 77%). 1H NMR
(600 MHz, CDCl3): δ [ppm] = 0.05 (s, 3H, SiCH3), 0.05 (s, 3H, SiCH3), 0.08 (s, 3H, SiCH3), 0.10 (s, 3H,
SiCH3), 0.86 (s, 9H, SiC(CH3)3), 0.91 (s, 9H, SiC(CH3)3), 1.47 (s, 9H, OC(CH3)3), 1.60–1.65 (m, 2H,
2′ ′-H), 2.39 (ddd, J = 11.6, 7.1, 6.9 Hz, 1H, 1′ ′-Ha), 2.84 (ddd, J = 11.6, 5.8, 5.8 Hz, 1H, 1′ ′-Hb), 3.26–3.36
(m, 3H, 6′-H, 3′ ′-H), 3.84 (dd, J = 7.2, 1.1 Hz, 1H, 5′-H), 4.07 (dd, 4.6, 1.1 Hz, 1H, 4′-H), 4.12 (dd, J = 4.6,
4.4 Hz, 1H, 3′-H), 4.36 (dd, J = 4.5, 4.4 Hz, 1H, 2′-H), 5.03 (dd, J = 6.2, 6.1 Hz, 1H, 3′ ′-NH), 5.08 (d, J =
12.2 Hz, 1H, 1′ ′ ′-Ha), 5.10 (d, J = 12.2 Hz, 1H, 1′ ′ ′-Hb), 5.52 (d, J = 4.5 Hz, 1H, 1′-H), 5.70 (d, J = 8.1 Hz,
1H, 5-H), 7.29–7.35 (m, 5H, aryl-H), 7.59 (d, J = 8.1 Hz, 1H, 6-H), 8.69 (s, 1H, 3-H). 13C NMR (126 MHz,
CDCl3): δ [ppm] = −4.71 (SiCH3), −4.67 (SiCH3), −4.62 (SiCH3), −4.23 (SiCH3), 17.99 (SiC(CH3)3),
18.11 (SiC(CH3)3), 25.82 (SiC(CH3)3), 25.90 (SiC(CH3)3), 28.13 (OC(CH3)3), 30.13 (C-2′ ′), 38.70 (C-3′ ′),
45.65 (C-1′ ′), 64.55 (C-6′), 66.67 (C-1′ ′ ′), 68.96 (C-5′), 72.18 (C-3′), 73.77 (C-2′), 82.19 (OC(CH3)3), 84.82
(C-4′), 92.31 (C-1′), 102.03 (C-5), 128.00, 128.08, 128.43 (aryl-C), 136.54 (C-2′ ′ ′), 141.81 (C-6), 149.94 (C-2),
156.38 (Cbz-C=O), 162.74 (C-4), 172.04 (C-7′). MS (ESI+): m/z = 793.5 [M + H]+. HRMS (ESI+): calcd.:
793.4234 [M + H]+, found: 793.4234. IR (ATR): ν [cm−1] = 1682, 1252, 1154, 1121, 867, 834, 813, 776,
735. UV (MeCN): λmax (log ε) = 204 (4.24), 261 (3.99). Optical rotation: [α]D25 = +18.0 (c = 0.55, CHCl3).
m.p. = 62 ◦C. TLC: Rf = 0.13 (2:3, petroleum ether:EtOAc).
Cbz-protected 5′-epi nucleoside building block (35): To a solution of uridine-derived epoxy
tert-butyl ester 34 (10 mg, 0.017 mmol) in i-PrOH (4 mL), N-benzyloxycarbonyl-1,3-diaminopropane
32 (5.4 mg, 0.026 mmol) was added and the mixture was stirred under reflux for 3 d. The solvent
was removed under reduced pressure, and the resultant crude product was purified by column
chromatography (97:3, CH2Cl2-MeOH) to give 35 as a colourless solid (12 mg, 89%). 1H NMR
(600 MHz, DMSO-d6, 35 ◦C): δ [ppm] = −0.07 (s, 3H, SiCH3), 0.01 (s, 3H, SiCH3), 0.08 (s, 3H, SiCH3),
0.11 (s, 3H, SiCH3), 0.81 (s, 9H, SiC(CH3)3), 0.89 (s, 9H, SiC(CH3)3), 1.42 (s, 9H, OC(CH3)3), 1.49–1.54
(m, 2H, 2′ ′-H), 2.04 (s, 1H, 6′-NH), 2.34 (ddd, J = 10.6, 8.5, 8.2 Hz, 1H, 1′ ′-Ha), 2.54 (ddd, J = 10.6, 7.1,
6.8 Hz, 1H, 1′ ′-Hb), 2.99–3.06 (m, 3H, 6′-H, 3′ ′-H), 3.70 (ddd, J = 6.3, 6.1, 5.4 Hz, 1H, 5′-H), 4.10 (d, J =
5.4 Hz, 1H, 4′-H), 4.23 (d, J = 4.4 Hz, 1H, 3′-H), 4.32 (dd, J = 7.7, 4.4 Hz, 1H, 2′-H), 5.00 (s, 2H, 1′ ′ ′-H),
5.58 (d, J = 6.3 Hz, 1H, OH), 5.67 (d, J = 8.1 Hz, 1H, 5-H), 5.87 (d, J = 7.7 Hz, 1H, 1′-H), 7.16 (dd, J =
5.9, 5.8 Hz, 1H, 3′ ′-NH), 7.33–7.36 (m, 5H, aryl-H), 7.73 (d, J = 8.1 Hz, 1H, 6-H), 11.31 (s, 1H, 3-H). 13C
NMR (126 MHz, DMSO-d6, 35 ◦C): δ [ppm] = −5.15 (SiCH3), −4.88 (SiCH3), −4.63 (SiCH3), −4.53
(SiCH3), 17.54 (SiC(CH3)3), 17.67 (SiC(CH3)3), 25.54 (SiC(CH3)3), 25.62 (SiC(CH3)3), 27.76 (OC(CH3)3),
30.07 (C-2′ ′), 38.44 (C-3′ ′), 44.96 (C-1′ ′), 64.21 (C-6′), 64.97 (C-1′ ′ ′), 71.89 (C-3′), 72.22 (C-5′), 73.76 (C-2′),
80.11 (OC(CH3)3), 85.66 (C-1′), 86.04 (C-4′), 102.09 (C-5), 127.43, 127.47, 128.07 (aryl-C), 137.02 (C-2′ ′ ′),
140.51 (C-6), 150.64 (C-2), 155.81 (Cbz-C=O), 162.52 (C-4), 171.66 (C-7′). MS (ESI+): m/z = 793.5 [M +
H]+. HRMS (ESI+): calcd.: 793.4234 [M + H]+, found: 793.4239. IR (ATR): ν [cm−1] = 1689, 1252, 1153,
1057, 833, 813, 775, 735, 697. UV (MeCN): λmax (log ε) = 204 (4.13), 259 (3.77). Optical rotation: [α]D25 =
−30.0 (c = 0.24, CHCl3). m.p. = 78 ◦C. TLC: Rf = 0.15 (96:4, CH2Cl2:MeOH).
4.2. Overexpression of MraY from S. aureus
The overexpression of MraY was performed as described before [48]. A plasmid containing
the mraY gene [48] was transformed into E. coli Lemo21 cells, which were plated on lysogeny broth
(LB) agar containing kanamycin (50 µg/mL) and chloramphenicol (30 µg/mL). A single colony was
picked to induce an overnight culture (10 mL) of LB media containing kanamycin (50 µg/mL) and
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chloramphenicol (30 µg/mL), which was incubated at 37 ◦C and 180 rpm for 16 h. A culture of LB
media (500 mL) containing kanamycin (50 µg/mL), chloramphenicol (30 µg/mL), and L-rhamnose
(1 mM) was inoculated with the overnight culture (500 µL) and then grown at 37 ◦C and 180 rpm
to OD600 0.6. Subsequently, MraY expression was induced with IPTG (1 mM) and the culture was
incubated at 37 ◦C and 180 rpm for 4 h. Cells were then centrifuged and the pellet was resuspended in
buffer A (50 mM Tris-HCl buffer pH 7.5, 1 mM MgCl2, 2 mM β-mercaptoethanol, 15 mL overall). Egg
white lysozyme (spatula tip), DNAse I (spatula tip), and cOmpleteTM EDTA-free protease inhibitor
cocktail (one tablet) were added. Cells were lysed using sonication and then incubated at 4 ◦C
for 30 min. The lysate was centrifuged and the supernatant was centrifuged again. The resultant
pellet was resuspended in buffer A (1.7 mL), flash frozen in liquid nitrogen and stored at −80 ◦C
(aliquots of 20 µL). This MraY-containing crude membrane preparation (overall protein concentration
~20.5 mg/mL as determined by OD280) was diluted with water (final overall protein concentration
1 mg/mL) and then directly used for MraY activity assays without further purification.
4.3. Fluorescence-Based MraY assay
The assay was performed as described before [40]. The crude membrane preparation of MraY from
S. aureus (1 µL, vide supra) was added to a mixture of undecaprenyl phosphate (50 µM), dansylated
Park′s nucleotide (7.5 µM) [48], and the tested compound (at varying concentrations) in buffer (100 mM
Tris-HCl buffer pH 7.5, 200 mM KCl, 10 mM MgCl2, 0.1% Triton X-100, 20 µL overall). Fluorescence of
the assay mixtures over time was monitored at λex = 355 nm and λem = 520 nm (plate reader, 384-well
plate format). MraY activity at a certain inhibitor concentration was determined using linear regression
from 0 to 2 min. This measure of activity was plotted against logarithmic inhibitor concentrations and
fitted using a sigmoidal fit. This procedure furnished IC50 values with standard deviations.
5. Conclusions
In summary, we have demonstrated that the synthesis of 5′-epi and 6′-epi muraymycin
analogues with retained inhibitory activities against the bacterial target enzyme MraY is feasible.
The 5′,6′-anti-configured 5′-hydroxy motif has been newly established as a versatile structural variation
in this context. In particular, (5′S,6′R)-derivatives (i.e., 5′-hydroxy-6′-epi analogues) appear to be
promising as their synthesis is highly efficient. Therefore, this novel scaffold will allow the introduction
of diverse variations of the 5′-O-aminoribose motif for further SAR studies, thus enabling the future
optimisation of MraY inhibitor potencies and the development of synthetic muraymycin analogues
towards antibacterial drug candidates. Work along this line is on the way in our laboratories.
Supplementary Materials: The following are available online, details on the analysis of peptide units using
Marfey’s reagent, copies of NMR spectra.
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